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The overall objectives of this research were to: (1) examine the determinants of 
implementation effectiveness of a community pharmacy population health management 
intervention and (2) compare the implementation process of high- and low-performing 
community pharmacies participating in a population health management intervention. 
We used a sequential mixed-methods research design to examine implementation of the 
Community Pharmacy Enhanced Services Network (CPESNSM) in North Carolina. Data sources 
included qualitative interviews and survey data linked with program administrative data from 
2016. The first study used a hurdle regression to examine the impact of organizational 
determinants on implementation effectiveness (e.g., implementation activity and program reach) 
(n=191). Community pharmacy’s implementation climate (AME = 2.65, p = 0.000) and 
innovation-values fit (AME = 2.17, p = 0.037) was significantly associated with implementation 
activity (e.g., implementation versus non-implementation). Similarly, pharmacy’s 
implementation climate (AME = 5.05, p = 0.001) and innovation-values fit (AME = 11.79, p = 
0.000) was significantly associated with program reach (e.g., amount of intervention delivered to 
target population).  
The second study identified the role of network ties to support implementation of NC-
CPESN and compared network ties among high- and low-performing pharmacies using thematic 
analysis of qualitative interviews (n=40). The study found that high-performing pharmacies had 
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a greater diversity of network ties (e.g., relationships with healthcare providers, care managers, 
and public health agencies) and were able to use those ties to support implementation of NC-
CPESN.  
The third study compared the implementation process of high- and low-performing NC-
CPESN community pharmacies using thematic analysis of qualitative interviews (n=40). 
Community pharmacies employed implementation strategies such as redefining job 
responsibilities to ensure pharmacists and pharmacy technicians are working at the top of their 
license. Findings also revealed differences in the implementation process among high- and low-
performing pharmacies, such as low-performing pharmacies omitting strategies used by high-
performers.  
In sum, organizational- and environmental-level determinants and differences in the 
implementation process affected implementation effectiveness of a community pharmacy 
population health management intervention. Payers supporting community pharmacy integration 
into population health management models should consider these factors affect implementation 
and develop implementation strategies accordingly.   
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CHAPTER 1. INTRODUCTION 
The Affordable Care Act has changed the organization, financing, and delivery of 
healthcare1 by implementing new payment models and financial incentives to encourage 
healthcare providers to accept and manage healthcare for a defined patient population.2 To this 
end, population health management programs have arisen that have common features such as 
identifying high-need, high-cost (HNHC) patients; tailoring care delivery to patients’ risk level; 
and coordinating care across a diverse team of healthcare and social service providers.3 One of 
the most challenging aspects of population health management is improving health outcomes for 
HNHC patients4 who often have complex health and social needs that can interfere with disease 
management.5-7 Pharmacists could play a critical role in population health management programs 
by delivering medication management services to HNHC patients. However, pharmacists have 
been underutilized in population health management models such as Accountable Care 
Organizations.8  
Community Care of North Carolina (CCNC)—North Carolina’s primary case 
management program for Medicaid beneficiaries—is currently piloting Community Pharmacy 
Enhanced Services Network (CPESNSM), a population health management intervention designed 
to both improve the quality and outcomes of healthcare and reduce healthcare costs for HNHC 
patients.9 Pharmacies participating in CPESN deliver intensive, one-on-one services to patients, 
often requiring pharmacy staff to work together in teams to effectively deliver services. Program 
participants include community pharmacies that are locally-owned, part of a chain, or outpatient 
pharmacies that are part of a health system.10 The evaluation of the CPESN pilot that is 
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underway does not assess its implementation effectiveness (the quality and consistency of 
implementation11,12), which is critical for decision-makers in North Carolina who seek to spread 
CPESN, as well stakeholders in other states that are considering similar programs.  
We used a sequential mixed-methods research design25 to examine implementation of the 
CPESN program in North Carolina. Using the organizational theory of implementation 
effectiveness11,12, the first study of this dissertation quantitatively examined the role of 
implementation climate, as well as the overall fit between CPESN and pharmacy’s mission and 
values, on implementation effectiveness in community pharmacies.13 This first study also 
examined the impact of other organizational determinants of implementation effectives that are 
identified by the consolidated framework for implementation research including patient needs 
and resources, available resources, access to information and knowledge, and structural 
characteristics.14  
The second study of this dissertation identified and compared the use of network ties to 
support implementation among high- and low-performing community pharmacies using 
qualitative methods. The second study also explored how network ties are formed and 
maintained to support implementation of CPESN. The third study compared the implementation 
strategies used at different stages of the innovation process among high- and low-performing 
community pharmacies. The implementation process unfolds in key phases, from agenda setting 
when an organization identifies a need for an innovation, through routinization when the 
innovation is no longer viewed as separate from day-to-day activities of the organization.15 
Within each of these phases, pharmacies use key implementation strategies to support the 
implementation process, such as planning, education, restructuring, quality-management, and 
finance strategies.16,17  
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The central hypothesis of this research was that key organizational and environmental 
determinants and the implementation process influence which pharmacies are more effective at 
implementing CPESN.  The long-term goal of this research is to increase successful 
implementation of population health management interventions in community pharmacies in the 
US. To test the central hypothesis, this dissertation examined implementation effectiveness of 
CPESN in approximately 255 community pharmacies in NC by pursuing the following Specific 
Aims:   
Aim 1: To examine the association between organizational determinants and 
implementation effectiveness of a population health management intervention in 
community pharmacies. 
Aim 2: To identify and compare the network ties used to support implementation of a 
population health management intervention among high- and low-performing community 
pharmacies.  
Aim 3: To identify and compare the implementation strategies of high- and low-
performing community pharmacies at different stages of the innovation implementation 
process.  
This dissertation used a sequential mixed-methods research design to examine 
implementation of the Community Pharmacy Enhanced Services Network (CPESNSM) in North 
Carolina. Data sources included qualitative interviews and survey data linked with program 
administrative data from 2016. The first study used a hurdle regression model to examine the 
impact of organizational determinants on implementation effectiveness (e.g., implementation 
activity and program reach). The second study used a thematic analysis of qualitative interviews 
to identify and compare the network ties used to support implementation of a population health 
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management intervention among high- and low-performing community pharmacies. Similarly, 
the third study used a thematic analysis of qualitative interviews to identify and compare the 
implementation strategies of high- and low-performing community pharmacies at different stages 
of the innovation implementation process. 
The aims from this dissertation were anticipated to produce the following outcomes: 1) 
contribute to understanding of the environmental and organizational determinants of 
implementation effectiveness of a population health management in community pharmacy, and 
2) Provide guidance to community pharmacy practitioners and policymakers on how to 
implement population health management interventions in community pharmacy settings. The 
results from this dissertation will be important for scaling up interventions like CPESN that seek 
to integrate community pharmacists into population health management models.   
The sections of this dissertation are organized as follows. Chapter 2 summarizes the 
current literature regarding population health management in community pharmacy. This chapter 
concludes with a statement regarding the significance and innovation of this research. Chapter 3 
provides an overview of the methods used in this dissertation including the conceptual 
framework, study design and rationale, study setting and sample, intervention description, data 
sources, and analytic approaches. Chapters 4-6 are manuscripts for Aims 1-3, respectively, and 
are intended for submission for peer-reviewed publication. Chapter 7 summarizes the findings of 
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CHAPTER 2. LITERATURE REVIEW 
High-Need, High-Cost Patients 
Nearly half of total healthcare expenditures are concentrated among five percent of the 
U.S adult population (12 million people).1,2 This small subset of the population is commonly 
referred to as high-need, high-cost (HNHC).3-5 HNHC patients have been defined in multiple 
ways; however, the most commonly used definition is patients with three or more chronic 
conditions and a functional limitation (e.g., cognitive, physical, or psychological).3-5 Studies 
have found that HNHC patients have higher annual expenditures on healthcare services and 
prescriptions and higher rates of preventable hospitalizations and emergency department use than 
the general population.3,4,6-8 Additionally, HNHC patients are more likely than the general 
population to report having unmet medical needs, lower satisfaction with patient-provider 
communication, and experiences of social isolation and loneliness.6,9 Several patient 
demographics are positively associated with HNHC status including age greater than 65, female 
gender, non-Hispanic ethnicity, White race, public insurance, lower educational attainment, and 
lower income.3,6,9   
 Within the Medicaid program, HNHC patients account for a large proportion of 
spending; five percent of Medicaid beneficiaries account for almost half of Medicaid 
expenditures.10 HNHC Medicaid patients are disproportionately impacted by costly chronic 
conditions, such as asthma and diabetes, and the co-occurrence of difficult-to-treat conditions, 
including mental health and substance use conditions.10 Medicaid HNHC patients more 
frequently report experiences of social isolation and loneliness and homelessness and housing 
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instability than other Medicaid beneficiaries.11 Several patient demographics are positively 
associated with HNHC status for Medicaid beneficiaries including older age, female gender, 
non-Hispanic ethnicity, and White race.12,13  
Pharmacist-led Medication Management Programs  
To improve care for HNHC patients, Medicaid and other payers have started shifting 
from fee-for-service to alternative payment models, which offer incentives for healthcare 
organizations to implement population health management strategies to increase the value, 
effectiveness, and efficiency of care.14,15 Population health management programs emphasize 
tailored interventions for HNHC patients who are at greater risk than the general population for 
medication errors16 and adverse drug events17,18, which, in turn, increase hospitalization risk.19  
Since pharmacists are highly trained in medication management, some population health 
management programs have included pharmacist-led medication management programs.20  
Pharmacist-led medication management programs have demonstrated success in 
changing patients’ medication behaviors and therapeutic outcomes while reducing healthcare 
costs.21-28 For example, pharmacist-led medication management programs have demonstrated 
success in identifying drug-related therapy problems29, improving disease management and 
medication adherence30,3144, and reducing inappropriate medication use.32 Additionally, 
community pharmacist-led medication management programs have positively affected patient 
outcomes including patients’ ability to manage their blood glucose, blood pressure, and LDL 
cholesterol.30,33,34 Studies have also reported that pharmacist-led medication management 





Implementation of Medication Management Programs  
Researchers have tried to determine which medication management program features are 
associated with changes in patient outcomes but have had difficulty finding a connection due to 
variation in program design.21,38 In the Medicare Part D Medication Therapy Management 
(MTM) program, for example, researchers have noted that medication services are delivered in a 
variety of settings (e.g., call centers, outpatient care) and formats (e.g., in-person vs. phone).21 
Similar challenges exist in Medicaid medication management programs—programs vary in 
patient eligibility criteria, the services provided, and the setting of service delivery.38 Some 
Medicaid pharmacist-led medication management programs, for example, involve having a 
pharmacist deliver medication management services in a primary care setting whereas other 
programs offer medication management services in community pharmacy settings.38  
In addition to program design variability, there are a limited number of studies examining 
implementation of medication management programs, making it difficult to assess why program 
outcomes might vary across organizations. Organizational context is important for understanding 
why implementation effectiveness may vary across settings and for identifying common factors 
across diverse settings that contribute to effective implementation. Many of the studies that have 
examined determinants of implementation effectiveness have been qualitative, limiting their 
generalizability, or have not been guided by a theory, making it difficult to interpret the findings. 
Past studies have identified factors, such as organizational structure (e.g., staff size), leadership 
support, and financial resource availability39-43, but not applied theory to demonstrate how these 
factors work in concert to produce effective implementation. 
The majority of studies that have examined implementation of pharmacist-led medication 
management services have not been conducted in community pharmacy settings. Several state 
Medicaid programs (NC, MN, WI) have launched medication management services in 
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community pharmacy settings38 but there are only two studies assessing implementation.44,45 One 
study focuses on factors associated with documentation of medication management services, 
rather than overall program implementation.44 The other study explores organizational factors 
associated with program implementation using bivariate analysis, making it difficult to assess 
which factors are associated with effective implementation holding other factors constant.45 This 
dissertation will address this research gap by using multivariate analysis to examine overall 
program implementation of the Community Pharmacy Enhanced Services Program--a Medicaid 
medication management program in a community pharmacy setting.   
Community Pharmacy Enhanced Services Program 
Community Care of North Carolina (CCNC)—North Carolina’s primary case 
management program for Medicaid beneficiaries—is currently piloting Community Pharmacy 
Enhanced Services Network (CPESN), a population health management intervention designed to 
both improve the quality and outcomes of healthcare and reduce healthcare costs for HNHC 
patients.46 Pharmacies participating in CPESN deliver intensive, one-on-one services to patients, 
often requiring pharmacy staff to work together in teams to effectively deliver services. Program 
participants include community pharmacies that are locally-owned, part of a chain, and or 
outpatient pharmacies that are part of a health system.47 The evaluation of the CPESN pilot that 
is underway does not assess its implementation effectiveness (the quality and consistency of 
implementation48,49), which is critical for decision-makers in North Carolina who seek to spread 
CPESN, as well stakeholders in other states that are considering similar programs.  
Significance and Innovation 
There is limited implementation research about medication management programs and 
more specifically, programs in community pharmacy settings.21,38,50 Having limited evidence 
about implementation makes it difficult for policymakers and practitioners to provide 
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implementation guidance or offer technical assistance to community pharmacies implementing 
medication management programs. Additionally, the lack of implementation research makes it 
impossible to spread and scale up effective practices or discontinue ineffective practices. This 
dissertation is significant for its potential to close this implementation gap by examining three 
key determinants of implementation effectiveness: organizational determinants (aim 1), 
environmental determinants (e.g., network ties) (aim 2), and the implementation process (aim 3).  
This study is innovative because it uses a theory-based approach to examine 
implementation effectiveness of a medication management program in a community pharmacy 
setting. Prior studies of medication management programs have not used a theory-based 
approach, making it difficult to assess how a combination of factors interacts to produce 
effective implementation. Additionally, this study quantitatively tests the organizational theory 
of innovation implementation48,49,51, which has only been quantitatively tested in a few 
studies48,52, and has never been tested in a community pharmacy setting. Therefore, the findings 
from this dissertation will contribute to implementation theory by determining whether the 
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CHAPTER 3. STUDY DESIGN AND METHODS 
Overview and Rationale  
This dissertation employed a sequential mixed-methods research design1 to understand 
implementation effectiveness of a community pharmacist-led medication management program 
for Medicaid beneficiaries. The purpose of the mixed-methods design was to use the qualitative 
findings from aims 2 and 3 to help explain the findings of the quantitative analysis of aim 1 (i.e., 
expansion).1 Aim 1 used a hurdle regression to examine the organizational determinants 
associated with implementation effectiveness (e.g., implementation activity and program reach). 
In Aim 2, a thematic analysis was conducted to identify and compare use of network ties to 
support implementation among high- and low-performing community pharmacies. Similarly, aim 
3 used a thematic analysis to identify and compare the implementation strategies used by high- 
and low-performing community pharmacies at each stage of the innovation process.  
Specific Aims and Hypotheses 
Aim 1: To examine the association between organizational determinants and 
implementation effectiveness of a population health management intervention in 
community pharmacies. 
Hypothesis 1a: Positive perceptions about implementation climate will be positively 
associated with implementation effectiveness. 
Hypothesis 1b: Positive perceptions about innovation-values fit will be positively 
associated with implementation effectiveness. 
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Hypothesis 1c: The impact of implementation climate on implementation effectiveness 
will be amplified by positive, and weakened by negative, perceptions about 
innovation-values fit (moderation).  
Hypothesis 1d: Four contextual factors (e.g., patient needs and resources, available 
resources, access to knowledge, and structural characteristics, will affect 
implementation effectiveness. 
Aim 2: To identify and compare the use of network ties to support implementation of a 
population health management intervention in community pharmacies among high- and 
low-performing pharmacies.  
Aim 3: To identify and compare the implementation strategies of high- and low-performing 
community pharmacies at different stages of the innovation implementation process.  
Conceptual Framework  
 Implementation theories have been developed to identify the organizational factors and 
underlying relationships that are hypothesized to influence effective implementation (i.e., the 
quality and consistency of implementation).2,3 The organizational theory of innovation 
implementation effectiveness was designed for complex innovations like medication 
management programs, which often require coordinated use by multiple individuals to be 
effective.3-5 This theory posits that effective implementation is driven by an organization’s 
implementation climate and the fit between the innovation and organization values (Figure 3.1).3-
5 For example, a community pharmacy might develop formal policies or strategies to support 
implementation of medication management programs such as employee training, reward and 
recognition systems, or job reassignment. The collective influence of the pharmacy’s 
implementation policies, in turn, affects employees’ shared perceptions about the extent to which 
the medication management program is rewarded, supported, and expected (implementation 
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climate).3-5 Positive perceptions about implementation climate are likely to increase employees’ 
acceptance of medication management programs, increasingly the likelihood that pharmacy staff 
will appropriately implement medication management programs (i.e., as the pharmacy intended 
for it to be implemented) and ultimately increase implementation effectiveness.  
 The organizational theory of innovation implementation effectiveness maintains that 
innovation-values fit also affects implementation effectiveness.3-5 Specifically, pharmacy 
employees’ perceptions about how well medication management programs align with the values 
of the pharmacy and the pharmacy profession affect implementation effectiveness both directly 
and indirectly. If pharmacy employees perceive that medication management programs do not 
align with the pharmacy’s values, the employee may be less committed to implementation and 
exert less effort towards ensuring effective implementation.3 Innovation-values fit is also likely 
to impact the relationship between implementation climate and implementation effectiveness. 3-5 
Since innovation-values fit affects commitment, the impact of implementation climate on 
implementation effectiveness will be amplified by positive, and weakened by negative, 
perceptions about innovation-values fit.  
 Implementation effectiveness is also likely to be affected by broader environmental and 
organizational factors (e.g., organizational context).6 Based on the consolidated framework for 
implementation research,6 we hypothesize four factors influence implementation effectiveness: 
patient needs and resources, available resources, access to knowledge and information, and 
structural characteristics.6 For example, community pharmacies that serve a higher proportion of 
high-need, high-cost patients may be better at implementing innovations for high-need, high-cost 
populations. Additionally, pharmacies in rural locations may be better at implementing 
innovations for high-need, high-cost populations since residents in rural areas have higher rates 
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of chronic illness.7 Implementation effectiveness is also likely to be positively influenced by a 
pharmacy’s available resources, such as amount of staff and training of staff, and access to 
knowledge and information about medication management programs (e.g., experience 
implementing similar interventions). Conversely, certain structural characteristics may 
negatively affect implementation effectiveness. For example, pharmacies that have opened 
recently may not have as strong of ties with patients as pharmacies that have been in operation 
for many years (e.g., the liability of newness hypothesis).8 Similarly, larger pharmacies may be 
impeded by a more formal organizational structure, which can negatively impact innovation 
implementation.9 For instance, managers of independently owned pharmacies may have greater 
decisional autonomy because there is less formalization in the organization and as a result, be 




Figure 3.1. The impact of implementation climate and innovation-values fit on 
implementation effectiveness  
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Study Setting and Sample 
The study was conducted with approximately 255 community pharmacies that 
participated in CPESN over the three-year program period (September 2014- August 2017). The 
community pharmacies were located throughout the state of NC in both rural and urban areas. 
The participating pharmacies served Medicaid, Medicare, dually eligible, and NC Health Choice 
Beneficiaries. Participating community pharmacies were located in various settings such as 
grocery stores and federally qualified health centers and included a mix of approximately locally 
owned and non-locally owned pharmacies such as chain pharmacies and outpatient pharmacies. 
The sample included 123 community pharmacies that enrolled in year 1 of the program, 107 
community pharmacies that enrolled in year 2 of the program, and 25 community pharmacies 
that enrolled in year 3 of the program. Within each pharmacy, staff that participated in 
implementing CPESN were surveyed including pharmacy owners or managers, the lead 
pharmacists, other pharmacists, pharmacy technicians, data entry specialists, and delivery 
drivers. Pharmacies varied in their staffing models to support CPESN. As an example, some 
pharmacies had only one staff member responsible for CPESN implementation, such as the 
owner, whereas other pharmacies had several pharmacists and technicians that supported 
CPESN. 
Intervention Description 
This dissertation examined the implementation of CPESN in North Carolina. CPESN is 
an open network of community pharmacies (meaning anyone that meets the requirements can 
participate) that have agreed to offer enhanced medication management services, document those 
services in PHARMACeHOME, and receive payment for those services based on performance. 
The medication management services are based on a population health management approach. 
CCNC identifies HNHC patients using their proprietary risk score based on chronic conditions 
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and disease severity; then, participating pharmacies deliver medication management services to 
those patients and coordinate that service with other providers in CCNC’s statewide patient-
centered medical home network. The specific enhanced medication management services that are 
offered are divided into required and optional services. One of the key services required for 
reimbursement is a comprehensive medication review (CMR) to identify opportunities for 
improving medication management and reduce risk of medication problems. CPESN is funded 
by a 3-year pilot grant from the Center for Medicare and Medicaid Innovation.  
Data Sources  
The three aims explored in this dissertation relied on both qualitative and quantitative 
data sources. Qualitative data were collected through in-depth, semi-structured interviews with 
community pharmacy representatives who were responsible for overseeing CPESN 
implementation. There were three sources of quantitative data including survey data, program 
administrative data, and county health ranking data.  
In fall 2016, we administered a paper-based survey to community pharmacies that 
participated in either the first or second year of the NC-CPESN program. The survey assessed 
pharmacies’ organizational characteristics, experience with NC-CPESN, and perceptions about 
implementation (e.g., implementation climate, innovation-values fit). A committee of researchers 
and community pharmacy practitioners reviewed the survey items’ content, readability, and 
formatting. The survey questions were also piloted in a small group of community pharmacists 
(n=5). The survey was mailed to participating pharmacies along with other NC-CPESN program 
materials to increase the response rate. Pharmacies also received three email reminders at ~2, 4, 
and 8 weeks after the survey was mailed. Within the pharmacy, employees that were intended 
users of NC-CPESN (e.g., pharmacists, pharmacy technicians, and administrative staff) 
completed the survey. We received surveys from 191 of 268 pharmacies (71.3% response rate).  
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 In addition, we used 2016 NC-CPESN program administrative data and 2016 county 
health ranking data.10 Program administrative data provided information on the number of high-
risk patients attributed to each pharmacy, patient demographics, and the amount of the 
intervention that was delivered. County health ranking data included county-level measures of 
clinical (e.g., healthcare access) and social (e.g., insurance status) factors that might affect the 
pharmacy’s implementation of NC-CPESN.10 The operationalization of these measures is 
described below.  
Variables and Measurement 
Aim 1 Measures 
Implementation of a CMR for high-risk patients. Based upon whether a pharmacy 
implemented a CMR on any attributed high-risk patient, we divided the sample into 
implementers (e.g., > 1 CMR for an attributed high-risk patient) and non-implementers (e.g., no 
CMR for any attributed high-risk patients) between Nov 2016 and Jan 2017. We chose this 
quarter because there were no changes to the intervention (e.g., intervention requirements or 
payment model) during this or the previous quarter. We measured implementation effectiveness 
over a quarter to correspond with CCNC’s performance measures. High risk was defined as 
having a care triage score > 75. Care triage score is a proprietary measure used by CCNC to 
estimate a patient’s risk for hospitalization. Patients with triage scores > 75 are considered a 
priority population for CCNC. Patients are defined as attributed to a pharmacy if they filled at 
least one chronic medication within the last 90 days or > 80% of their medications for at least 
two of three months within the quarter.   
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Proportion of high-risk patients receiving a CMR. Second, we measured implementation 
effectiveness to assess the reach of the intervention among attributed high-risk patients. We 
calculated the number of attributed high-risk patients receiving a CMR divided by the number of 
high-risk, attributed patients per pharmacy during a program quarter.  
Independent Variables 
 
Implementation climate. Implementation climate was defined using four survey items 
assessing the extent to which NC-CPESN was supported, rewarded, and expected within the 
pharmacy (e.g., “Our pharmacy allocates sufficient time to delivering enhanced pharmacy 
services” and “Our pharmacy devotes adequate resources to implementing enhanced pharmacy 
services”).3-5 The questions included group rather than individual referents, which is 
recommended when assessing organizational-level outcomes such as implementation climate.11 
Each item was measured on 5-point Likert scale ranging from 0 (strongly disagree) to 4 (strongly 
agree). The survey items were summed for individual staff members, and the mean of all 
individuals in the pharmacy was calculated to produce a pharmacy-level measure. Higher values 
of the score corresponded with positive perceptions of implementation climate.  
Innovation-values fit. Innovation-values fit was defined using four survey items assessing 
staff perceptions about the extent to which NC-CPESN fit with the values of the pharmacy (e.g., 
“Delivering enhanced pharmacy services is consistent with providing the best care possible for 
our patients)” and of the pharmacy profession (“Delivering enhanced pharmacy services is 
important for advancing the field of pharmacy”).3-5 As with implementation climate, the 
innovation-values fit questions were group-referenced, measured on the same 5-point Likert 
scale, aggregated from individual responses to produce a pharmacy-level mean, and ordered so 
that higher scores corresponded to positive perceptions.  
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Other independent variables. Patients’ needs and resources were measured by rural 
location, clinical factors, social factors, 340B participation, and proportion of high-risk patients. 
Rural location was defined as a binary variable (e.g., urban, rural) using a zip code 
approximation of the rural-urban commuting area (RUCA) codes. Clinical factors were defined 
using a pre-existing, county-level composite measure of access to care items (e.g., primary care 
provider ratio, uninsured rate) and quality of care items (e.g., preventable hospital stays, diabetes 
monitoring) ranging from 0-100.10 Social factors were defined using a pre-existing, county-level 
composite measure of items such as education, employment, uninsured, and income ranging 
from 0-100.10 The clinical and social factor scales were recoded so that higher values on the 
scale were associated with better patient outcomes. Participation in 340B Drug Pricing Program 
was measured as a binary variable. Proportion of high-risk patients was defined as the number of 
attributed high-risk patients divided by the number of attributed patients per pharmacy over a 
program quarter.   
 Available resources were measured by three variables: the presence of a clinical 
pharmacist (binary), total number of full- and part-time staff (e.g., pharmacists, pharmacy 
technicians, administrative staff), and the presence of pharmacy students or residents in the past 
month (binary).      
 Access to knowledge and information about the intervention was measured in three ways: 
(1) experience with NC-CPESN, defined as the number of months the pharmacy was enrolled in 
NC-CPESN; (2) past performance with NC-CPESN, measured using a lagged dependent variable 
(e.g., proportion of CMRs completed per high-risk patients) for the previous program quarter 
(Aug – Oct 2016); and (3) participation in Medicare Part D MTM (binary).  
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 Structural characteristics were assessed by three variables. First, independent ownership 
was a binary variable: single and multiple independent pharmacies versus chain, outpatient, and 
federally qualified health center pharmacies. We used a binary variable due to small sample sizes 
within the chain and outpatient pharmacy categories. Second, prescription volume was 
dichomotized as low (< 2000 prescriptions/week) versus high (>2000 prescriptions/week). Third, 
established pharmacies were those that had been in operation for more than 20 years.   
Aim 2 and Aim 3 Measures 
 A semi-structured interview guide was developed to explore environmental determinants 
of implementation effectiveness (e.g., network ties) (aim 2) and the stages of the innovation 
process from Rogers’ stages of the innovation process in organizations (aim 3).6,12 During the 
first half of the interview, participants were asked to describe the strategies the pharmacy used to 
implement CPESN at various stages of implementation (e.g., pre-implementation, 
implementation, and sustainment).12 During the first half of the interview, participants were 
asked to describe their pharmacy’s relationships with external organizations (e.g., healthcare 
providers, care managers) and relationships with patients. 
Data Analysis by Aim 
Aim 1 
Descriptive statistics. Frequencies and percentages were used to describe the study 
population. We conducted bivariate analyses to compare the sample characteristics between 
implementers (completed > 1 CMR during the program quarter) and non-implementers (no 
completed CMR during the program quarter).   
Exploratory factor analyses. To determine if survey items could be adequately 
summarized using implementation climate and innovation-values fit scales, we first assessed 
whether the correlation matrix was factorable by examining the pairwise correlations among the 
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items and conducting a Barlett’s test of sphericity and a Kaiser-Meyer-Olkin (KMO) test. 
Second, we defined the number of initial factors using principal component analysis using 
orthogonal varimax rotation to improve interpretability. Finally, we confirmed the number of 
extracted factors using two decision rules: 1) eigenvalue >1 and 2) the number of eigenvalues 
from the factor analysis that are larger than the eigenvalues from randomly generated data (e.g., 
parallel analysis test). We assessed the reliability of the two scales using Cronbach’s alpha. To 
ensure the results were not sensitive to the method of factor extraction, we ran a common factor 
analysis using principal axis factoring and did not find differences in the results. Since the 
measures of implementation climate and innovation-values fit were aggregated from multiple 
staff roles within the pharmacy (e.g., pharmacists, pharmacy technicians, and administrative 
staff), we compared the results of the exploratory factor analyses by these sub-groups and did not 
find differences in the results. Since all of the implementation climate and innovation-values fit 
items were measured using similar Likert scales of measurement, we did not standardize the 
scores (e.g., z scores) prior to conducting the exploratory factor analysis.  
Hurdle regression model. Hurdle regression is a two-equation model for count data: one 
equation determines the likelihood of an outcome (e.g., whether a pharmacy implemented a 
CMR) and the other examines the positive outcomes (e.g., how many CMRs were delivered to 
high-risk patients).13,14 We used a hurdle regression to model both of these processes and to 
account for an excess of zeroes in the dependent variable (40.8% of the sample had zero 
implementation in the program quarter). For the first stage, we used a logistic regression to 
determine the probability of a pharmacy implementing a CMR for a high-risk patient (e.g., 
implementer versus non-implementer). For the second stage, we used a zero-truncated negative 
binomial model to determine how many CMRs were delivered to high-risk patients (e.g., 
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program reach). A negative binomial model was selected over a Poisson model to account for 
overdispersion in the data (i.e., the variance was larger than the mean). For the negative binomial 
model, we treated the denominator (i.e., number of high-risk patients) as the exposure to adjust 
for differences in the opportunity available to deliver the intervention and assumed the 
unobserved heterogeneity was gamma distributed (i.e., NB2 model). We compared this model 
with a zero-inflated negative binomial, which is another two-equation model for count data; we 
did not find differences in the results. Therefore, we used the hurdle regression.   
In the hurdle regression, we included the key variables of interest (e.g., implementation 
climate, innovation-values fit, and an interaction of the two) and control variables selected a 
priori (e.g., patient needs and resources, available resources). We assessed the goodness of fit for 
the interaction term in both stages of the model since interpretation of marginal effects on 
interaction terms can be complicated in non-linear models.15 Since the interaction term improved 
fit in both stages, we included the term. One control variable, past performance with NC-
CPESN, was a lagged dependent variable, which can caused biased coefficients if the data 
generating process is non-stationary.16 Using the Harris-Tzavalis test17, which can be used when 
the number of time periods is small relative to the number of panels, we rejected the null 
hypothesis that the data generating process is non-stationary. Therefore, we included the lagged 
dependent variable in the model. We used cluster-robust standard errors to account for clustering 
that might occur at the network level. NC-CPESN pharmacies are grouped into regional 
networks by CCNC and may receive different levels and quality of implementation support 
across networks. Because the amount of missing data in both equations of the model was less 
than 10% (8.0% and 5.8% respectively), we addressed missingness using complete case analysis. 
To test whether missingness might be correlated with the dependent variable, we compared the 
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proportion of implementers and non-implementers between survey respondents and non-
respondents and did not find significant differences (𝒳2 = 2.27, p =0.132). We conducted the 
analyses using Stata version 13.0 (College Station, TX). 
Aim 2 and Aim 3 
For Aims 2 and 3, thematic analysis was conducted using Dedoose (version 7.0) to 
analyze the qualitative data. First, a set of structural codes were developed based on Roger’s 
theory 12,18 and the CFIR.6 Two members of the research team coded five transcripts to: 
determine how similarly codes were being applied; develop a set of emergent codes18; and reach 
consensus on code definitions. One author coded the remaining transcripts. After transcripts were 
coded, a summary was sent to three of the interview participants to confirm the findings; this 
member-checking process helps ensure that the interpretation is consistent with the experiences 
of study participants.19 Interview participants who were consulted agreed with the interpretation 
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CHAPTER 4. ORGANIZATIONAL DETERMINANTS THAT INFLUENCE 
IMPLEMENTATION EFFECTIVENESS IN A COMMUNITY PHARMACY MEDICAID 
MEDICATION MANAGEMENT PROGRAM 
Introduction 
 Many state Medicaid programs have expanded enrollment eligibility under the 
Affordable Care Act, making Medicaid the largest health insurance program in the U.S.1,2 
Medicaid spending is largely driven by a small subset of high-risk patients; five percent of 
Medicaid beneficiaries account for almost half of Medicaid expenditures.3 This small subset of 
beneficiaries is disproportionately impacted by chronic conditions, such as diabetes and asthma, 
and the co-occurrence of difficult-to-treat conditions (e.g., substance use and mental health 
conditions).3 To improve chronic disease management, several Medicaid programs have 
implemented medication management programs in partnership with pharmacists.4-6 
Pharmacist-led medication management programs have improved patients’ medication 
adherence and therapeutic outcomes (e.g., blood pressure, hemoglobin A1C) while reducing 
healthcare costs.7-10 However, researchers have had difficulty attributing changes in patient 
outcomes to specific program features due to the wide variability in medication management 
programs.4,11 In the Medicare Part D Medication Therapy Management (MTM) program, for 
example, researchers have noted that medication services are delivered in a variety of settings 
(e.g., call centers, outpatient care) and formats (e.g., in-person vs. phone).11 Similar challenges 
exist in Medicaid medication management programs—programs vary in patient eligibility 
criteria, the services provided, and the setting of service delivery.4  
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In addition to program design variability, there are a limited number of studies examining 
implementation of pharmacist-led medication management programs, making it difficult to 
assess why program outcomes might vary across organizations. Many of the studies that have 
examined organizational determinants of implementation effectiveness in pharmacist-led 
medication management programs have been qualitative, limiting their generalizability, or have 
not been guided by a theory, making it difficult to interpret the findings. Past studies have 
identified factors, such as organizational structure (e.g., staff size), leadership support, and 
financial resource availability12-16, but not applied theory to demonstrate how these factors work 
in concert to produce effective implementation. Thus, this study will test the applicability of the 
organizational theory of innovation implementation effectiveness to examine implementation of 
a community pharmacy Medicaid medication management program. 
Conceptual Framework  
 Implementation theories have been developed to identify the organizational factors and 
underlying relationships that are hypothesized to influence effective implementation (i.e., the 
quality and consistency of implementation).17,18 The organizational theory of innovation 
implementation effectiveness was designed for complex innovations like medication 
management programs, which often require coordinated use by multiple individuals to be 
effective.18-20 This theory posits that effective implementation is driven by an organization’s 
implementation climate and the fit between the innovation and organization values (Figure 
4.1).18-20 For example, a community pharmacy might develop formal policies or strategies to 
support implementation of medication management program such as employee training, reward 
and recognition systems, or job reassignment. The collective influence of the pharmacy’s 
implementation policies, in turn, affects employees’ shared perceptions about the extent to which 
the medication management program is rewarded, supported, and expected (implementation 
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climate).18-20 Positive perceptions about implementation climate are likely to increase 
employees’ acceptance of medication management programs, increasingly the likelihood that 
pharmacy staff will appropriately implement medication management programs (i.e., as the 
pharmacy intended for it to be implemented) and ultimately increase implementation 
effectiveness. Therefore, we hypothesize that positive perceptions about implementation climate 
will be positively associated with implementation effectiveness (H1).  
 The organizational theory of innovation implementation effectiveness maintains that 
innovation-values fit also affects implementation effectiveness.18-20 Specifically, pharmacy 
employees’ perceptions about how well medication management programs align with the values 
of the pharmacy and the pharmacy profession affect implementation effectiveness both directly 
and indirectly. If pharmacy employees perceive that medication management programs do not 
align with the pharmacy’s values, the employee may be less committed to implementation and 
exert less effort towards ensuring effective implementation.18 Innovation-values fit is also likely 
to impact the relationship between implementation climate and implementation effectiveness. 18-
20 Since innovation-values fit affects commitment, the impact of implementation climate on 
implementation effectiveness will be amplified by positive, and weakened by negative, 
perceptions about innovation-values fit. Thus, we hypothesize that positive perceptions about 
innovation-values fit will directly and positively affect implementation effectiveness (H2) and 
moderate the relationship between implementation climate and implementation effectiveness 
(H3).  
 Implementation effectiveness is also likely to be affected by broader environmental and 
organizational factors (e.g., organizational context).21 Based on the consolidated framework for 
implementation research (CFIR),21 we hypothesize four factors influence implementation 
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effectiveness: patient needs and resources, available resources, access to knowledge and 
information, and structural characteristics.21 For example, community pharmacies that serve a 
higher proportion of high-risk patients may be better at implementing innovations for high-risk 
populations. Additionally, pharmacies in rural locations may be better at implementing 
innovations for high-risk populations since residents in rural areas have higher rates of chronic 
illness.22 Implementation effectiveness is also likely to be positively influenced by a pharmacy’s 
available resources, such as amount of staff and training of staff, and access to knowledge and 
information about medication management programs (e.g., experience implementing similar 
interventions). Conversely, certain structural characteristics may negatively affect 
implementation effectiveness. For example, pharmacies that have opened recently may not have 
as strong of ties with patients as pharmacies that have been in operation for many years (e.g., the 
liability of newness hypothesis).23 Similarly, larger pharmacies may be impeded by a more 
formal organizational structure, which can negatively impact innovation implementation.24 For 
instance, managers of independently owned pharmacies may have greater decisional autonomy 
because there is less formalization in the organization and as a result, be better able to support 
implementation of medication management programs. Therefore, we hypothesize that four 
contextual factors, patient needs and resources, available resources, access to knowledge, and 
structural characteristics, will affect implementation effectiveness (H4).   
Methods 
Study Design 
 We used a cross-sectional design examining implementation of a community pharmacy 
Medicaid medication management program during the program year of 2016. The unit of 




The community pharmacy enhanced services network (CPESNSM) is a national network 
of community pharmacies that offer medication management services.25 This study examines the 
North Carolina CPESN (NC-CPESN), the pioneer site for CPESN.6 NC-CPESN was launched in 
2014 by the Community Care of North Carolina (CCNC)—the primary case management 
provider for NC Medicaid beneficiaries.6,26 NC-CPESN requires community pharmacies to: (1) 
provide certain medication management services; (2) be pharmacies responsible for the 
outcomes of a defined patient population through value-based payment; and (3) tailor services 
based on patients’ risk score. One of the key services required for reimbursement is a 
comprehensive medication review (CMR) to identify opportunities for improving medication 
management and reduce risk of medication problems. Patients include Medicaid, Medicare, and 
NC Health Choice beneficiaries, as well as dual-eligible patients.  
Study Population  
The study population included community pharmacies that participated in either the first 
year or the second year of the 3-year NC-CPESN program (September 2014-August 2017); 
pharmacies that joined in the third year were excluded from the analysis because they had little-
to-no experience with implementation at the time of the survey (described below). We excluded 
results of surveys completed in August 2017 because the intervention (e.g., requirements for 
delivering a CMR) and payment model (e.g., amount of payment per CMR) changed and we did 
not think implementation measures would be comparable at the two time points.  
Data Sources 
 In fall 2016, we administered a paper-based survey to community pharmacies that 
participated in either the first or second year of the NC-CPESN program. The survey assessed 
pharmacies’ organizational characteristics, experience with NC-CPESN, and perceptions about 
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implementation (e.g., implementation climate, innovation-values fit). A committee of researchers 
and community pharmacy practitioners reviewed the survey items’ content, readability, and 
formatting. The survey questions were also piloted in a small group of community pharmacists 
(n=5). The survey was mailed to participating pharmacies along with other NC-CPESN program 
materials to increase the response rate. Pharmacies also received three email reminders at ~2, 4, 
and 8 weeks after the survey was mailed. Within the pharmacy, employees that were intended 
users of NC-CPESN (e.g., pharmacists, pharmacy technicians, and administrative staff) 
completed the survey. We did not include supporters of NC-CPESN (e.g., pharmacy owners) 
since their actions indirectly rather than directly affect implementation, a decision that is 
consistent with other implementation studies.19,27 We often had more than one respondent per 
pharmacy; therefore, the responses were aggregated to the pharmacy-level (description below). 
We received surveys from 191 of 268 pharmacies (71.3% response rate).  
 In addition, we used 2016 NC-CPESN program administrative data and 2016 county 
health ranking data.28 Program administrative data provided information on the number of high-
risk patients attributed to each pharmacy, patient demographics, and the amount of the 
intervention that was delivered. County health ranking data included county-level measures of 
clinical (e.g., healthcare access) and social (e.g., insurance status) factors that might affect the 
pharmacy’s implementation of NC-CPESN.28 The operationalization of these measures is 
described below.  
Dependent Variables 
Implementation of a CMR for high-risk patients. Based upon whether a pharmacy 
implemented a CMR on any attributed high-risk patient, we divided the sample into 
implementers (e.g., > 1 CMR for an attributed high-risk patient) and non-implementers (e.g., no 
CMR for any attributed high-risk patients) between Nov 2016 and Jan 2017. We chose this 
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quarter because there were no changes to the intervention (e.g., intervention requirements or 
payment model) during this or the previous quarter. We measured implementation effectiveness 
over a quarter to correspond with CCNC’s performance measures. High risk was defined as 
having a care triage score > 75. Care triage score is a proprietary measure used by CCNC to 
estimate a patient’s risk for hospitalization. Patients with care triage scores > 75 are considered a 
priority population for CCNC. Patients are defined as attributed to a pharmacy if they filled at 
least one chronic medication within the last 90 days or > 80% of their medications for at least 
two of three months within the quarter.  
Proportion of high-risk patients receiving a CMR. Second, we measured implementation 
effectiveness to assess the reach of the intervention among attributed high-risk patients. We 
calculated the number of attributed high-risk patients receiving a CMR divided by the number of 
high-risk, attributed patients per pharmacy during a program quarter.  
Independent Variables 
Implementation climate. Implementation climate was defined using four survey items 
assessing the extent to which NC-CPESN was supported, rewarded, and expected within the 
pharmacy (e.g., “Our pharmacy allocates sufficient time to delivering enhanced pharmacy 
services” and “Our pharmacy devotes adequate resources to implementing enhanced pharmacy 
services”).18-20 The survey items were adapted for a pharmacy setting from a scale validated in an 
oncology setting.29,30 The questions included group rather than individual referents, which is 
recommended when assessing organizational-level outcomes such as implementation climate.27 
Each item was measured on 5-point Likert scale ranging from 0 (strongly disagree) to 4 (strongly 
agree). The survey items were summed for individual staff members, and the mean of all 
individuals in the pharmacy was calculated to produce a pharmacy-level measure. Higher values 
of the score corresponded with positive perceptions of implementation climate.  
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Innovation-values fit. Innovation-values fit was defined using four survey items assessing 
staff perceptions about the extent to which NC-CPESN fit with the values of the pharmacy (e.g., 
“Delivering enhanced pharmacy services is consistent with providing the best care possible for 
our patients)” and of the pharmacy profession (“Delivering enhanced pharmacy services is 
important for advancing the field of pharmacy”).18-20 As with implementation climate, the 
innovation-values fit questions were group-referenced, measured on the same 5-point Likert 
scale, aggregated from individual responses to produce a pharmacy-level mean, and ordered so 
that higher scores corresponded to positive perceptions.  
Other independent variables. Patients’ needs and resources were measured by rural 
location, clinical factors, social factors, 340B participation, and proportion of high-risk patients. 
Rural location was defined as a binary variable (e.g., urban, rural) using a zip code 
approximation of the rural-urban commuting area (RUCA) codes. Clinical factors were defined 
using a pre-existing, county-level composite measure of access to care items (e.g., primary care 
provider ratio, uninsured rate) and quality of care items (e.g., preventable hospital stays, diabetes 
monitoring) ranging from 0-100.28 Social factors were defined using a pre-existing, county-level 
composite measure of items such as education, employment, uninsured, and income ranging 
from 0-100.28 The clinical and social factor scales were recoded so that higher values on the 
scale were associated with better patient outcomes. Participation in 340B Drug Pricing Program 
was measured as a binary variable. Proportion of high-risk patients was defined as the number of 
attributed high-risk patients divided by the number of attributed patients per pharmacy over a 
program quarter.   
 Available resources were measured by three variables: the presence of a clinical 
pharmacist (binary), total number of full- and part-time staff (e.g., pharmacists, pharmacy 
 
41 
technicians, administrative staff), and the presence of pharmacy students or residents in the past 
month (binary).      
 Access to knowledge and information about the intervention was measured in three ways: 
(1) experience with NC-CPESN, defined as the number of months the pharmacy was enrolled in 
NC-CPESN; (2) past performance with NC-CPESN, measured using a lagged dependent variable 
(e.g., proportion of CMRs completed per high-risk patients) for the previous program quarter 
(Aug – Oct 2016); and (3) participation in Medicare Part D MTM (binary).  
 Structural characteristics were assessed by three variables. First, independent ownership 
was a binary variable: single and multiple independent pharmacies versus chain, outpatient, and 
federally qualified health center pharmacies. We used a binary variable due to small sample sizes 
within the chain and outpatient pharmacy categories. Second, prescription volume was 
dichomotized as low (< 2000 prescriptions/week) versus high (>2000 prescriptions/week). Third, 
established pharmacies were those that had been in operation for more than 20 years.   
Statistical Analysis  
Descriptive statistics. Frequencies and percentages were used to describe the study 
population. We conducted bivariate analyses to compare the sample characteristics between 
implementers (completed > 1 CMR during the program quarter) and non-implementers (no 
completed CMR during the program quarter).   
Exploratory factor analyses. To determine if implementation climate and innovation-
values survey items could be used as distinct variables, we conducted three analyses. First, we  
examined pairwise correlations among the items and conducted a Barlett’s test of sphericity and 
a Kaiser-Meyer-Olkin (KMO) test. Second, we defined the number of initial factors using 
principal component analysis and rotated the factors using orthogonal varimax rotation to 
improve interpretability. Finally, we confirmed the number of extracted factors using two 
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decision rules: 1) the number of eigenvalues >1.0; and 2) the number of eigenvalues from the 
factor analysis that were larger than the eigenvalues from randomly generated data (e.g., parallel 
analysis test). We also assessed the internal consistency of the two scales using Cronbach’s 
coefficient alpha. To ensure the results were not overly sensitive to the method of factor 
extraction, we conducted a sensitivity analysis by running a common factor analysis using 
principal axis factoring and did not find differences in the results. We also compared the results 
of the exploratory factor analyses by staff roles within pharmacies (e.g., pharmacists, pharmacy 
technicians, and administrative staff) to determine if results from different staff types could be 
aggregated to the pharmacy level. Factor analyses did not differ by subgroup, suggesting that 
aggregating subgroups was appropriate. . 
Hurdle regression model. Hurdle regression is a two-equation model for count data: one 
equation determines the likelihood of an outcome (e.g., whether a pharmacy implemented a 
CMR) and the other examines the positive outcomes (e.g., how many CMRs were delivered to 
high-risk patients).31,32 We used a hurdle regression to model both of these processes and to 
account for an excess of zeroes in the dependent variable (40.8% of the sample had zero 
implementation in the program quarter). For the first stage, we used a logistic regression to 
determine the probability of a pharmacy implementing a CMR for a high-risk patient (e.g., 
implementer versus non-implementer). For the second stage, we used a zero-truncated negative 
binomial model to determine how many CMRs were delivered to high-risk patients (e.g., 
program reach). A negative binomial model was selected over a Poisson model to account for 
overdispersion in the data (i.e., the variance was larger than the mean). For the negative binomial 
model, we treated the denominator (i.e., number of high-risk patients) as the exposure to adjust 
for differences in the opportunity available to deliver the intervention and assumed the 
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unobserved heterogeneity was gamma distributed (i.e., NB2 model). We compared this model 
with a zero-inflated negative binomial, which is another two-equation model for count data; we 
did not find differences in the results. Therefore, we used the hurdle regression.   
In the hurdle regression, we included the key variables of interest (e.g., implementation 
climate, innovation-values fit, and an interaction of the two) and control variables selected a 
priori (e.g., patient needs and resources, available resources). We assessed the goodness of fit for 
the interaction term in both stages of the model since interpretation of marginal effects on 
interaction terms can be complicated in non-linear models.33 Since the interaction term improved 
fit in both stages, we included the term. One control variable, past performance with NC-
CPESN, was a lagged dependent variable, which can caused biased coefficients if the data 
generating process is non-stationary.34 Using the Harris-Tzavalis test35, which can be used when 
the number of time periods is small relative to the number of panels, we rejected the null 
hypothesis that the data generating process is non-stationary. Therefore, we included the lagged 
dependent variable in the model. We used cluster-robust standard errors to account for clustering 
that might occur at the network level. NC-CPESN pharmacies are grouped into regional 
networks by CCNC and may receive different levels and quality of implementation support 
across networks. Because the amount of missing data in both equations of the model was less 
than 10% (8.0% and 5.8% respectively), we addressed missingness using complete case analysis. 
To test whether missingness might be correlated with the dependent variable, we compared the 
proportion of implementers and non-implementers between survey respondents and non-
respondents and did not find significant differences (𝒳2 = 2.27, p =0.132). We conducted the 




 Of the 191 pharmacies in our sample, 113 (59.16%) were implementers. Pharmacies that 
successfully implemented a CMR had a significantly higher mean implementation climate (11.81 
vs. 3.55, p=0.000) and innovation-values fit (13.55 vs. 11.06, p=0.000) scores (Table 4.1). In 
terms of patient needs and resources, implementing pharmacies were significantly more likely to 
participate in the 340B Drug Pricing Program (69.12% vs. 30.88%, p=0.024) and have a higher 
proportion of high-risk patients (0.42 vs. 0.36, p=0.004). For available resources, implementing 
pharmacies were more likely to have a clinical pharmacist (86.49% vs. 13.51%, p=0.000) and 
either a pharmacy student or resident on staff (92.86 vs. 7.14%, p=0.000). Implementing 
pharmacies had more experience with NC-CPESN (34.37 vs. 27.05, months p=0.000) and had a 
higher proportion of CMRs performed among high-risk patients in the previous quarter (0.03 vs. 
0.00, p=0.000). For structural characteristics of pharmacies, we did not find any significant 
differences among implementers versus non-implementers.  
Exploratory Factor Analysis  
All pairwise correlations among the items in the implementation climate and innovation-
values scales were greater than >.30, indicating there was sufficient correlation for factor 
analysis. Further, none of the pairwise correlations exceeded >.80, indicating that high 
multicollinearity was not a problem. The Bartlett’s test of sphericity was significant for the 
implementation climate (𝒳2 = 1975.43, p = 0.000) and the innovation-values fit scale (𝒳2 =
1077.83, p = 0.000). Therefore, we rejected the null hypothesis that either matrix was an 
identity matrix. The KMO statistic for implementation climate and innovation-values fit scales 
was 0.773 and 0.818, respectively, which are within an acceptable range to support factor 
analysis (greater than >.60).36 
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 Factor loadings produced from the principal component analysis (Table 4.3) suggest that 
survey items measuring implementation climate or innovation-values fit load onto two distinct 
factors. For each set of items, only one factor had an eigenvalue exceeding 1.0 (implementation 
climate: largest EV = 2.77; innovation-values fit: largest EV = 3.35), and these eigenvalues were 
greater than eigenvalues from a randomly generated data set, suggesting one factor should be 
extracted for each set of items. The total amount of variance in the items explained by the two 
extracted factors was 79.27% for implementation climate and. 83.63% for innovation-values fit. 
There were several items that had double factor loadings (e.g., loaded onto more than one factor) 
(Table 4.3); however, based on our decision rules as well as our theory we retained one extracted 
factor for each set of items. Cronbach’s coefficient alpha was 0.845 for the implementation 
climate scale and 0.833 for the innovation-values scale, suggesting the items have ‘very good’ 
internal consistency.37 
Hurdle Regression: Equation 1   
 Hypothesis 1. The first equation of the hurdle regression indicated that a one-unit increase 
in the implementation climate score increased the probability of NC-CPESN implementation by 
2.65 percentage points holding all else constant (p=0.000) (Table 4.4). The predicted probability 
of NC-CPESN implementation for pharmacies with the median implementation climate score 
(9.14) was 0.66 compared to 0.84 for pharmacies with an implementation climate score at the 
75th percentile (12.50).  
Hypothesis 2. Similarly, an increase in innovation-values fit score increased the 
probability of NC-CPESN implementation by 2.17 percentage points (p=0.037). The predicted 
probability of NC-CPESN implementation for pharmacies with the median innovation-values 
score (13.07) was 0.61 compared to 0.66 for pharmacies with an implementation climate score at 
the 75th percentile (14.68).  
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Hypothesis 3. The marginal effect of innovation-values fit on the probability of NC-
CPESN implementation increased as implementation climate score increased. The marginal 
effect began to decline at an implementation score of 8 (Figure 4.2).  
Hypothesis 4. No significant differences in the probability of NC-CPESN implementation 
was found based on patients’ needs and resources. For available resources, the probability of 
implementing NC-CPESN was 9.86 percentage points higher for pharmacies that had a clinical 
pharmacist (p=0.038). In terms of access to knowledge and resources, amount of experience with 
NC-CPESN (p=0.004), past performance with NC-CPESN (p=0.000), and participation in 
Medicare Part D MTM (p=0.003) were each positively associated with the probability of 
implementing NC-CPESN. Within structural characteristics, the probability of implementing 
NC-CPESN was 4.14 percentage points higher among independently owned pharmacies 
(p=0.041).   
Hurdle Regression: Equation 2   
 Hypothesis 1. Findings from the second equation of the hurdle regression indicated that a 
one-unit increase an implementation climate score was associated with a 5.05 increase in 
implementation of CMRs per high-risk patients holding all else constant (p=0.001). The 
predicted number of CMRs per high-risk patients for pharmacies with the median 
implementation-climate score (9.14) was 16.21 compared to 28.10 for pharmacies with an 
implementation climate score at the 75th percentile (12.50).  
Hypothesis 2. Similarly, implementation of CMRs per high-risk patients was positively 
associated with innovation-values fit score (p=0.000). The predicted number of CMRs per high-
risk patients for pharmacies with the median innovation-values score (13.07) was 32.09 




Hypothesis 3. The marginal effect of innovation-values fit on the number of CMRs per 
high-risk patients increased as implementation climate score increased (Figure 4.3). 
Hypothesis 4. In terms of patients’ needs and resources, pharmacies located in rural 
locations were associated with lower implementation of CMRs per high-risk patients (p=0.006). 
Conversely, pharmacies that participate in the 340B Drug Pricing Program were associated with 
higher implementation (p=0.026). For available resources, pharmacies with a clinical pharmacist 
were associated with higher implementation (p=0.002). However, an increase in total staff was 
associated with a 1.98 decrease in implementation of CMRs per high-risk patients (p=0.000). For 
available resources, implementation of CMRs per high-risk patients was positively associated 
with experience with NC-CPESN (p=0.004), past performance with NC-CPESN (p=0.000), and 
participation in Medicare Part D MTM (p=0.003). No significant differences in implementation 
were found based on structural characteristics.  
Discussion 
 In this study, we used the organizational theory of innovation implementation 
effectiveness18-20 to test organizational factors that influence implementation effectiveness of a 
community pharmacy medication management intervention. Consistent with our hypothesis, we 
found that key constructs from this theory, such as implementation climate and innovation-
values fit, were positively associated with implementation activity (e.g., implementation versus 
non-implementation) and program reach of NC-CPESN. To our knowledge, only one other 
quantitative study has examined the relationship between implementation climate and 
implementation effectiveness in healthcare,29 and no other study has explored the direct and 
indirect effects of innovation-values fit on implementation effectiveness. Contrary to our 
hypotheses of contextual factors, only certain factors, such as having a clinical pharmacist on 
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staff, participation in Medicare Part D MTM or 340B Drug Pricing Program, predicted both 
implementation activity and program reach.  
 We hypothesized that implementation climate and innovation-values fit would be 
positively and directly associated with implementation effectiveness, which was supported by 
our findings. These findings suggest that implementation climate and innovation-values fit were 
useful measures for predicting implementation activity and program reach. Further studies are 
needed to test whether these measures are predictive of implementation effectiveness across a 
wider variety of community pharmacy medication management programs. For example, we 
learned from previous qualitative work that NC-CPESN community pharmacy staff worked 
collaboratively to implement CMRs. For other medication management programs, organizations 
may rely on a single staff member to deliver the intervention and therefore group-level measures 
such as implementation climate may not be predictive of implementation effectiveness. In such 
settings, individual-referenced measures of implementation climate30 may be more valid.   
 The study results also supported the hypothesis that innovation-values fit moderates the 
effect of implementation climate on implementation effectiveness, indicating that 
implementation climate and innovation-values fit work in concert. Our findings also suggest that 
innovation-values fit may have a greater effect on implementation climate at lower levels of 
implementation climate and that the effect may diminish at higher levels of implementation 
climate (Figure 4.2). Further research is needed to establish whether there are diminishing 
returns to the effect of innovation-values fit on implementation climate and whether the 
relationship changes based on whether the outcome of interest is presence of implementation 
activity versus level of implementation activity (e.g., program reach). Additionally, future 
research is needed to determine what factors are positively associated with implementation 
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climate and innovation-values fit in community pharmacy medication management programs. 
For example, the organizational theory of innovation implementation effectiveness18-20 maintains 
that management support is an antecedent of implementation climate but there has been little 
quantitative research on how to operationalize the construct of management support. Recently, 
researchers have developed a measure for implementation leadership to assess which leadership 
qualities are correlated with successful implementation.38 Future studies could assess whether 
implementation leadership is associated with implementation climate. This has practical 
importance because identifying the leadership strategies and traits associated with effective 
implementation could provide guidance to pharmacy leaders on how to develop a supportive 
climate for medication management program implementation.   
 Contrary to our hypotheses, we found that only certain aspects of the organizational 
context affected both program reach and implementation activity. For example, none of the 
structural characteristics (e.g., pharmacy type, established pharmacy) were significantly 
associated with both program reach and implementation activity. Additional research is needed 
to determine which pharmacy structural characteristics are associated with successful 
implementation. Consistent with our hypotheses, access to knowledge and information (e.g. 
participation in Medicare Part D MTM), patient needs and resources (e.g., proportion of high-
risk patients, participation in 340B Drug Pricing Program), and availability of certain resources 
(e.g., clinical pharmacist) positively affect implementation effectiveness. Prior theory suggests 
that establishing an implementation climate for one intervention may help facilitate 
implementation climate for a similar intervention.27 It is possible that community pharmacies use 
similar policies to support MTM and medication management services implementation (e.g., 
staff training on motivational interviewing)—explaining the positive association between 
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Medicare Part D MTM and NC-CPESN implementation. Future studies should use qualitative 
methods to explore the implementation policies and practices that community pharmacies 
establish to foster a climate for medication management services and whether these practices 
facilitate implementation of similar interventions. Such studies could be used to develop 
implementation guidance to support community pharmacies participating in multiple medication 
management programs simultaneously, which may increase as pharmacy participation in 
alternative payment models grows.  
Limitations 
This study had several limitations. First, since we measured implementation climate, 
innovation-values fit, and implementation effectiveness at the same time, we cannot establish the 
causal order. Second, the generalizability of our findings is limited by: (1) only having data at 
one time point; (2) conducting the study in NC, the first CPESN organization. Future studies are 
needed that to examine implementation of medication management programs over time and 
across settings. Third, our measures of implementation effectiveness, implementation activity 
and program reach among high-risk patients, are limited in scope and do not assess other 
important aspects of implementation effectiveness such as fidelity of CMR delivery. Future 
studies are needed to establish additional measures of implementation effectiveness (e.g., 
conducting site observations to measure CMR fidelity). Finally, we did not measure other 
determinants of implementation effectiveness including the presence of an innovation champion 
or variability in implementation climate perceptions.18-20 Future studies should develop and test 




As more state Medicaid programs adopt pharmacist-led medication management 
programs, it is important to identify what organizational determinants promote effective 
implementation of these programs. Our study supported the use of the organizational theory of 
innovation implementation effectiveness to identify organizational determinants that are 
associated with effective implementation (e.g., implementation climate and innovation-values 
fit).18-20 Unlike broader environmental factors or structural characteristics (e.g., pharmacy type), 
implementation climate and innovation-values fit are modifiable factors and can be targeted 
through intervention. Additional research is needed to determine what implementation strategies 
can be used by community pharmacy leaders and practitioners to develop a positive 




Figure 4.1. The impact of implementation climate and innovation-values fit on 
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Table 4.1. Descriptive statistics of community pharmacies participating in NC-CPESN 
 
Characteristics  Implementers  
(n=113) 
Mean (SD) or % 
Non-Implementers  
(n=78) 
Mean (SD) or % 
Total 
(n=191) 




Key independent variables  









   Innovation-values fit 13.55 (2.0218) 11.06 (3.99)*** 12.51 (3.231) 0-16 
Patient needs and resources     
   Rural location  57.78 42.22 23.56 0-1 
   Clinical factors 31.94 (29.78) 39.63 (29.40) 35.08 (29.8) 1-100 
   Social factors 44.07 (30.8) 46.36 (33.17) 45.01 (31.8) 1-100 
   340B participation 69.12 30.88* 36.76 0-1 
   Proportion of high-risk patients 0.42 (0.14) 0.36 (0.18)** 0.40 (0.16) 0-0.87 
Available resources     
   Presence of a clinical pharmacist 86.49 13.51*** 19.37 0-1 
   Total number of staff 12.83 (6.464) 11.53 (8.827) 12.30 (7.525) 1-40 
   Presence of pharmacy student or   
   resident 
92.86 7.14*** 21.99 0-1 
Access to knowledge and 
information 
    
   Amount of experience with NC-   
   CPESN (months) 
34.37 (7.0546) 27.05 (7.96)*** 31.38 (8.249) 12.1-44.7 
   Past performance with NC-CPESN 0.03 (0.04) 0.00 (0.00)** 0.02 (0.0) 0-0.31 
   Participation in Medicare Part D  
   MTM 
67.27 32.73*** 86.39 0-1 
Structural characteristics     
   Independent pharmacy 57.83 42.17 43.46 0-1 
   Low prescription volume 56.06 43.94 34.55 0-1 
   Established pharmacy  45.13 30.77 39.27 0-1 
Note: significance of t-tests or Pearson chi-square tests comparing implementers to non-implementers: * p<0.05, ** 





Table 4.2. Correlation matrix for the implementation climate and innovation-values fit 
scales  
 
 Implementation Climate   Innovation-values Fit  




1.000    1 
Professional 
values 




0.697 1.000   2 
Organizational 
values 
0.640 1.000   
3 
Expectation 
0.573 0.636 1.000  3 
Organizational 
values 
0.661 0.677 1.000  
4 
Reward 
0.486 0.531 0.493 1.000 4 
Professional 
values 





Table 4.3. Factor loadings from the rotated factor structure matrix for implementation 
climate and innovation-values fit scales 
 
Implementation Climate Items Factors 
1 2 3 4 
[Support - Time] Our pharmacy allocates sufficient time to delivering 
enhanced pharmacy services.  
0.523 -0.293 -0.396 0.644 
[Support - Resources] Our pharmacy devotes adequate resources to 
implementing enhanced pharmacy services. 
0.543 -0.296 -0.218 -0.055 
[Expectation] In our pharmacy, we are expected to participate in the 
delivery of enhanced pharmacy services.  
0.487 -0.037 0.565 0.114 
[Reward] In our pharmacy, individuals receive recognition for 
participating in the delivery of enhanced pharmacy services. 
0.442 0.610 -0.216 0.040 
Innovation-Values Fit Items Factors 
1 2 3 4 
[Professional values] Delivering enhanced pharmacy services is what 
pharmacies should be doing. 
0.498 -0.224 0.651 -0.232 
[Organizational values] Delivering enhanced pharmacy services is 
consistent with providing the best care possible for our patients. 
0.501 -0.068 -0.128 0.369 
[Organizational values] Delivering enhanced pharmacy services is 
important for improving health outcomes for our patient population. 
0.506 0.406 -0.308 -0.096 
[Professional values] Delivering enhanced pharmacy services is 
important for advancing the field of pharmacy. 
0.495 0.185 0.295 0.371 
Note: Underlined factor loadings indicate double loading on two or more factors. Factor loadings in bold indicate 




Table 4.4. Parameter estimates from Hurdle regression of NC-CPESN Implementation and 
Program Reach of NC-CPESN Implementation  
 








Key independent variables  
   Implementation climated 
 
 2.65 (1.85 X 103)c*** 
 
5.05 (1.5)** 
   Innovation-values fitd  2.17 (1.041 X 102)* 11.79 (3.170)*** 
Patient needs and resources   
   Rural location -0.77 (0.016) -12.81 (4.658)** 
   Clinical factors -0.04 (3 X 104) -0.14 (0.11) 
   Social factors -0.06 (3 X 104) -0.10 (0.10) 
   340B participation  5.70 (3.50 X 102)* 12.80 (5.760)* 
   Proportion of high-risk patients  0.00 (0.00)* — 
   Log of high-risk patients —             (exposure) 
Available resources   
   Presence of a clinical pharmacist  9.86 (4.75 X 102)*  32.33 (10.670)*** 
   Total number of staff -0.31 (2.6 X 103) -1.98 (0.550)*** 
   Presence of pharmacy student or   
   resident 
 6.86 (6.37 X 102)  14.55 (7.273) 
Access to knowledge and information    
   Amount of experience with NC-   
   CPESN (months) 
 0.43 (1.3 X 103)**  1.57 (0.610)*** 
   Past performance with NC-CPESN  0.46 (1.3 X 102)***  0.10 (0.031)*** 
   Participation in Medicare Part D  
   MTM 
18.73 (6.246 X 102)**  28.05 (13.83)* 
Structural characteristics   
   Independent pharmacy 4.14 (2.02 X 102)*  0.43 (5.6) 
   Low prescription volume 1.08 (0.032)  7.23 (7.21) 
   Established pharmacy  2.02 (0.015) 4.14 (7.46) 
Alpha — 0.56 (7.08 X 102)** 
Constant -21.04 (4.79)*** -14.03 (1.383)*** 
Observations 180 104 
Significance of hurdle regression: * p<0.05, ** p<0.01, *** p<0.001 
a. AME, average marginal effect 
b. Effect sizes for the stage 1 model are in percentage points; for example, 9.86 for presence of clinical pharmacist 
indicates that the probability of implementing NC-CPESN was 9.86 percentage points higher for pharmacies that 
have a clinical pharmacist.  
c. Any standard errors that were carried out to the ten-thousandths place value or smaller are represented in scientific 
notation.  
d. Equation 1 and 2 include an interaction term (implementation climate*innovation-values fit), which is represented 




Figure 4.2. Plot of marginal effect of innovation-values fit at representative values of 







Figure 4.3. Plot of marginal effect of innovation-values fit at representative values of 
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CHAPTER 5. THE ROLE OF NETWORK TIES TO SUPPORT IMPLEMENTATION 
OF A COMMUNITY PHARMACY ENHANCED SERVICES NETWORK 
Introduction 
Over the past two decades, the number of individuals with multiple chronic conditions 
(MCC) has grown, requiring more time and resources from primary care.1-3 To treat patients with 
MCC, primary care providers must address a large number of health issues within a short visit, 
manage unrelated conditions that require separate treatment plans (e.g., hypertension and 
depression), and coordinate care with other providers.4-7 Failure to effectively coordinate care 
across providers has resulted in suboptimal care for patients with MCC, leading to medication 
errors and preventable hospital admissions.8,9 Team-based care models, such as patient-centered 
medical homes and chronic care models, have improved outcomes for patients with MCC and 
increased system efficiency by allowing primary care providers to collaborate with other 
providers including pharmacists.10-17 Traditionally, team-based care models with pharmacists 
have been implemented in primary care settings;15-17 however, public and private payers have 
started implementing these programs in community pharmacy settings.18-20  
 Community pharmacist-led medication management programs have improved patients’ 
medication adherence and therapeutic outcomes (e.g., blood pressure, blood glucose).21-25 Given 
the effectiveness of these services, many payers are working to scale up and spread existing 
community pharmacy medication management programs.18,19,26 One approach being used to 
scale up these programs is community pharmacy enhanced service networks comprised of 
pharmacies that offer a set medication management services, manage care for a defined patient 
population, and coordinate services with other healthcare providers as part of an alternative 
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payment model.44 Enhanced service networks also provide chronic care management, which 
includes systematic assessment of patients’ medical and psychosocial needs, development of a 
comprehensive care plan, and longitudinal follow-up.27 However, limited evidence exists on how 
to implement enhanced service networks, as the inclusion of community pharmacy services into 
alternative payment models is relatively new.28,29  
 Studies of similar interventions, such as primary care pharmacy services, have found that 
implementation is largely impacted by the pharmacists’ relationship with other healthcare 
providers and patients.30-34 Studies have found, for example, that physicians may lack knowledge 
of pharmacists’ clinical training or be unfamiliar with pharmacists’ role in patient care and 
pharmacists may have difficulty negotiating clear role boundaries with physicians.33,34 
Additionally, studies have found that patients’ may lack knowledge of or be reluctant to use 
pharmacists’ medication management services.35 Building relationships with other healthcare 
providers and patients may be even more challenging in community pharmacy settings. 
Community pharmacists may not be co-located or working from the same electronic health 
record system as the healthcare providers they are partnering with.36,37 Patients may also lack 
awareness of community pharmacy services or be reluctant to have health information shared 
with community pharmacies.38,39 Therefore, research is needed to examine how community 
pharmacies facilitate relationships with other providers and patients under team-based care 
arrangements in community pharmacy settings.  
Study Objectives 
The aims of this study are to: (1) identify the role of network ties to support 
implementation of a community pharmacy enhanced services network, (2) describe how these 
network ties are formed and maintained, and (3) compare the role of network ties among high- 




Pharmacist participation in team-based care models requires relationship building or 
establishing network ties with providers in other healthcare and social service agencies (e.g., 
physicians, care managers). A pharmacy’s network ties can be characterized by the number and 
types of ties that exist (e.g., whether a pharmacy partners with organizations in pharmacy or non-
pharmacy industries)40 and the strength of the relationship between ties (e.g., trust and reciprocal 
sharing of resources).41 The formation of network ties depends on the pharmacy’s ability to 
navigate its external environment. For example, a pharmacy might create boundary-spanning 
roles that link staff members to outside organizations or hire leaders or new staff with beneficial 
social ties.40,42-44 The likelihood that a pharmacy will maintain a relationship with its network ties 
depends on several factors including whether the organizations have a history working together, 
are connected through multiple relationships (e.g., partnering on a grant and being members of a 
coalition), and use active strategies to maintain the partnership (e.g., putting formal 
communication structures in place).41 Once formed, a pharmacy’s network ties can facilitate 
implementation of interventions, such as team-based care models, by increasing adoption of 
evidence-based practices and transfer of knowledge and resources across organizations.41,44,45 
 In addition to forming ties with other organizations, pharmacies participating in team-
based care models need to establish ties with patients. A pharmacy’s ability to build relationships 
with patients is influenced by whether patient-centered care is made a priority by leadership46 as 
reflected in an organization’s policies and practices.47,48 Pharmacies might, for example, 
implement practices for identifying patients’ needs, resources, or preferences such as risk and 
patient-reported outcomes assessment tools49-51, patient decision support tools,52 or conversation 
guides.53 Similarly, pharmacies might change services based on patient needs or preferences 
(e.g., tailoring), partner with external organizations that have more resources to better address 
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patients’ needs and preferences, or develop patient advisory boards.54-56 To maintain 
relationships with patients over time, pharmacies can use clear and transparent communication, 
get to know patients’ personal and medical history, and engage in shared decision-making to 
gain patients’ trust, which, in turn, influences whether patients return to a particular provider.39,57 
The cycle is reinforcing—the more a patient visits a particular provider, the greater the 
likelihood that trust is established.57 Building ties with patients can also facilitate implementation 
of interventions44, such as team-based care models, by improving patient engagement and 
satisfaction with healthcare services.50,58,59  
Methods 
Study Setting  
The community pharmacy enhanced services network (CPESNSM) is a national network 
of community pharmacies that have agreed to offer chronic disease prevention and management 
services.26 This study examines the North Carolina CPESN (NC-CPESN), the pioneer site for 
CPESN.18 The NC-CPESN was launched in 2014 by the Community Care of North Carolina 
(CCNC)—the primary case management provider for NC Medicaid beneficiaries.18,60 NC-
CPESN not only requires community pharmacies to provide certain chronic disease prevention 
and management services but it also attributes a defined patient population to the pharmacy, 
holds pharmacies responsible for the outcomes of those patients through value-based payment, 
and requires pharmacies to tailor services based on patients’ risk score. Additionally, community 
pharmacies participating in NC-CPESN must develop a comprehensive care plan for patients and 
document care plans, services delivered, and patients’ clinical information in a web-based 
platform provided by CCNC. Patients include Medicaid, Medicare, and NC Health Choice 
beneficiaries, as well as dual-eligible patients that have MCC. Community pharmacies are 
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assigned a regional network pharmacist from CCNC that provides technical assistance and 
support.  
Study Sample 
Pharmacies in NC-CPESN represent diverse settings (e.g., independent, chain, and 
federally-qualified outpatient pharmacies). Pharmacies also range in their program performance 
as indicated by risk-adjusted, performance measures (e.g., medication adherence, emergency 
department utilization, hospital admissions, and total healthcare costs). To obtain diverse 
perspectives about implementation, we recruited a mix of high- and low- performing pharmacies. 
High-performing pharmacies were defined as pharmacies that had an above or at the mean 
overall performance score (e.g., a score that is an aggregate measure of the performance 
measures listed above) whereas low performing was defined as having a score below the mean. 
Because chain and federally qualified outpatient pharmacies comprise a smaller percentage of 
NC-CPESN pharmacies, we oversampled them to ensure they would be represented. 
To recruit participants, we asked pharmacies to identify the individual in their pharmacy 
responsible for, and most knowledgeable about, NC-CPESN implementation, offering them a 
$50 gift card for study participation. Five pharmacies declined to participate due to lack of time. 
We were able to recruit an additional five community pharmacies. We stopped recruitment after 
40 pharmacies (24 high performing, 16 low performing) since theme saturation was reached.61  
Data Collection 
Two trained research assistants (KT and CR conducted 40 in-depth interviews (mean = 
51 minutes) from June – August 2017. We chose interviews to best understand individual 
perspectives about NC-CPESN implementation.62 We developed a semi-structured interview 
guide based on Rogers’ stages of innovation theory and the CFIR.63,44,62 Interviews were 
conducted over the phone to facilitate participation across the State. The interviews were audio-
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record and transcribed verbatim. Prior to beginning the interview, participants provided informed 
consent over the phone. The Institutional Review Board of the University of North Carolina at 
Chapel Hill approved this study (IRB # 17-1304). 
Data Analysis  
 We analyzed the transcripts using Dedoose (version 7.0). We used thematic analysis to 
generate a set of structural codes that were based on network ties theory.40,42-44 We categorized 
network ties into three main categories: inter-personal ties (e.g., between individuals), inter-
organizational ties (e.g., between organizations), and ties with patients. Within each category, we 
examined three questions: 1) how ties are formed, 2) how ties facilitate NC-CPESN 
implementation, and 3) how ties are maintained. Two members of the research team (KT and 
CR) coded five transcripts to determine how similarly codes were being applied; develop a set of 
emergent codes (e.g., themes that emerge from the data)62; and reach consensus on code 
definitions. The remaining transcripts were coded by one author (KT). After transcripts were 
coded, a summary of the results were sent to three of the interview participants to confirm the 
findings; this member-checking process helps ensure that the interpretation is consistent with the 
experiences of the study participants.64 The interview participants who were consulted agreed 
with the interpretation of the findings and did not suggest any modifications. We used the 
Consolidated Criteria for Reporting Qualitative Studies checklist to guide our reporting of 
qualitative methods and findings.65 
Results 
Sample Characteristics  
 The majority of participants had a single role within the pharmacy (Table 5.1). The 
sample included a mix of high- (60%) and low-performing (40%) pharmacies from single 
independently owned pharmacies (20%), multiple independently owned pharmacies (50%), 
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chain pharmacies (10%), and outpatient pharmacies including federally qualified health centers 
(20%); this distribution is similar to pharmacies participating in NC-CPESN. On average, 
pharmacies in this sample employed 2.6 full-time equivalent (FTE) pharmacists, 4.0 FTE 
pharmacy technicians, and a total of 12.5 staff members (full-time and part-time). In terms of 
weekly prescription volume, 35.2% of pharmacies reported filling 1,000 or fewer prescriptions, 
34.6% reported between 1,001 and 2,000 prescriptions, and 30.3% reported more than 2,001 
prescriptions. About half of pharmacies (54.9%) had been in operation for ten years or more.   
Interpersonal Ties  
Tie formation. High- and low-performing pharmacies described how pharmacy owners 
and employees formed interpersonal ties with pharmacy colleagues; however, only high 
performing pharmacies discussed ties with non-pharmacy colleagues. Many pharmacy owners 
and staff members had developed interpersonal ties through pharmacy professional 
organizations, schools of pharmacies, and pharmaceutical distributors. Pharmacy owners and 
staff from high-performing pharmacies also developed ties with non-pharmacy colleagues, such 
as healthcare providers, by joining local civic or business organizations, participating in parent 
teacher associations, or by serving on hospital or other healthcare organizations’ board of 
directors.   
Role of ties in implementation. Both high- and low- performing pharmacies used their 
interpersonal ties with pharmacy colleagues to gain an awareness of NC-CPESN; however, only 
high-performing pharmacies used their ties to gain information about NC-CPESN 
implementation (Table 5.2). Specifically, high- and low-performing community pharmacies 
indicated that their pharmacy learned about NC-CPESN because of the pharmacy owners’ 
relationship with pharmaceutical distributors, professional pharmacy organizations, and 
pharmacies that were considered early adopters of NC-CPESN. Pharmacy owners and staff from 
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high-performing pharmacies obtained advice from their interpersonal ties about NC-CPESN 
implementation on training staff, documenting enhanced services efficiently, and incorporating 
enhanced services into workflow. A small subset of owners from high-performing pharmacies 
also used their external ties to arrange for their personnel to conduct observations and receive 
training in early-adopter, NC-CPESN pharmacies to learn how to best implement NC-CPESN. A 
pharmacy technician explained, “Our owner set up a time for me to go and observe at [name of 
pharmacy]. Their pharmacist sat down with me, showed me how to use the web-based platform, 
and what they [CCNC] was looking for as far as reimbursement.”  
A small number of high-performing pharmacies described using their interpersonal ties 
with healthcare providers to facilitate NC-CPESN implementation. Specifically, these pharmacy 
staff reported reaching out to their friends who are healthcare providers to discuss NC-CPESN 
and determine what barriers or facilitators might be encountered during implementation from the 
providers’ perspective, Additionally, pharmacy staff asked their provider colleagues for 
recommendations of other local healthcare providers who might be interested in participating in 
NC-CPESN. Providers included physicians, physician’s assistants, nurses, and nurse 
practitioners.  
Maintenance of ties. A small group of high- and low-performing pharmacies described 
using strategies to maintain their inter-personal ties with pharmacy colleagues, particularly staff 
in other pharmacies participating in NC-CPESN. Staff described the importance of sharing 
resources, such as tools for NC-CPESN implementation (e.g., co-management protocol 
templates) and referring patients to their pharmacist colleagues for services that their own 
pharmacy may not offer. This was not widespread however. Many pharmacies described the 
challenges of collaborating with other pharmacies that are perceived as competitor pharmacies, 
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even though the pharmacies are part of the same network. One pharmacist explained, “We are a 
part of this network but at the same time we are still competitors. I think that limits resource 
sharing unless you already have a strong relationship with that pharmacy.” 
High-performing pharmacies described strategies to maintain ties with their healthcare 
provider colleagues such as setting up monthly meetings and inviting their colleagues to attend 
pharmacy events such as annual award ceremonies. Participants described the importance of 
regular meetings so that their healthcare provider colleagues are aware of the services in their 
pharmacy. 
Inter-organizational Ties  
 Formation of ties. High-performing pharmacies had developed ties with other healthcare 
provider organizations, care management organizations, and public health agencies whereas low-
performing pharmacies did not have such relationships. High-performing pharmacies described 
how their relationships with other healthcare organizations often developed due to physical 
proximity to a provider’s office (e.g., having one next door or across the street). Independently 
owned pharmacies also described how it was easier to partner with independently-owned 
physician practices because the organizations’ shared a similar, less-formalized organizational 
structure. Pharmacies described how many of their relationships with healthcare providers were 
initiated by the pharmacy rather than by the healthcare provider.  
 A smaller group of high-performing pharmacies had also formed relationships with care 
management organizations (e.g., CCNC) and public health agencies (e.g., local agencies on 
aging, public health departments). These relationships were most often facilitated by previous 
collaboration on similar interventions. Additionally, several pharmacies explained that they 
initiated relationships with care managers and public health agencies because of a need to 
improve care for high-risk patients. One pharmacist shared, “We were not equipped to identify 
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patients at risk for [opioid] overdose or how to educate patients on naloxone. We’ve reached out 
to our health department and have had a lot of great meetings about how to work with those 
patients and how to have that conversation [about naloxone].” 
 Role of ties in implementation. Participants from high-performing pharmacies indicated 
that relationships with healthcare providers enabled NC-CPESN implementation by making 
providers aware of the pharmacy’s services and the clinical knowledge of pharmacists while 
increasing provider trust in the pharmacy. One pharmacy owner remarked, “We were already 
working closely with our doctors. That rapport was built before we joined CPESN. I think that 
made it easier for the physicians to accept the therapeutic recommendations we were making.” 
High-performing pharmacies also collaborated with other providers to gain information about 
patient needs. For example, pharmacies reported calling primary care providers to discuss the 
health history of patients experiencing medication problems or adherence issues. Low-
performing pharmacies, on the other hand, described difficulty obtaining patient information 
from providers due to lack of pre-existing relationships. 
High-performing pharmacies used ties with care managers to gain information about 
patients’ social needs. As an example, one pharmacist explained, “If they have other needs like 
need for home health, things like that, we can engage a care manager to help with some of the 
needs that as a pharmacist we may not feel comfortable doing or don’t have the resources 
available.” Pharmacies also used care managers to help engage patients in time-intensive 
interventions such as home visits. One pharmacy owner described, “Whenever we do a home 
visit we like for the care manager to join us. The care manager knows that patient better and the 
patient is going to be more receptive to us [pharmacy staff].” In contrast, a few of the low-
performing pharmacies indicated that they could see the value in working with care managers but 
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had not considered it and had never reached out to the care managers during their participation in 
NC-CPESN. 
 Maintenance of ties. High-performing pharmacies used strategies to maintain their 
relationships with other healthcare providers, such as updating providers on patients’ health 
issues and inviting providers to pharmacy events. High-performing pharmacies, for example, 
used strategies such as preparing patient report cards for physicians to make them aware of 
changes in medication adherence or inviting primary care practice staff to attend pharmacy 
events such as annual awards ceremonies for pharmacy employees. One pharmacy owner 
explained, “We send a report card to the physician to let them know how their [the patient’s] 
adherence is. If we identify any medication problems when we’re talking to them [the patient] 
each month, we stay in close contact with the physician’s office. That keeps the lines of 
communication open.” Since low-performing pharmacies were building relationships with 
healthcare providers for the first time, some described using strategies such as arranging face-to-
face meetings with providers to introduce them to the pharmacy’s services. However, most low-
performing pharmacies did not describe using any strategies to build relationships with 
healthcare providers outside of routine communication about specific patients.  
Pharmacy owners at high-performing pharmacies created staff positions with boundary 
spanning roles—a strategy that was not used by low-performing pharmacies to maintain 
relationships with providers. For example, high-performing pharmacies had pharmacists who 
worked in healthcare provider offices for 1-2 days a week and collaborated with providers at co-
sponsored healthcare fairs or immunization events. Some high-performing pharmacies also had 
healthcare providers, such as nurses or dieticians, work in their pharmacy for 1-2 days a week. 
Participants explained that boundary-spanning helped the pharmacy to learn about the priorities 
 
73 
and goals of healthcare providers (e.g., meeting performance measurement goals) and to increase 
healthcare providers’ knowledge about the clinical skills of pharmacists and community 
pharmacy services. One pharmacy manager described, “We [the owner and the manager] created 
a partnership with a local [primary care] practice where I work there one day a week and assist 
with annual wellness visits. It’s been great for me to get a better understanding of their 
[physician’s] day-to-day and it helps the physicians to gain a better understanding of what 
pharmacists can do.” 
To maintain relationships with care managers, some high-performing pharmacies set up 
regular monthly meetings to discuss difficult-to-treat patients or ideas for additional 
collaborations (e.g., new medication management services that could be supported by care 
manager involvement). For the small group of pharmacies working with public health agencies, 
they were at the relationship formation rather than maintenance stage.  
Ties with Patients 
 Formation of ties. Both high- and low-performing pharmacies described how factors such 
as years of operation and staff knowledge about the local community helped facilitate ties with 
patients. Pharmacies that had been operating in the community for many years, for example, had 
frequent interactions with certain high-risk patients and had gained their trust over time. 
Additionally, staff members’ knowledge of the local community such as location of community 
resources (e.g., behavioral health agencies) helped facilitate relationships with patients by 
allowing staff members to serve as resources for patients. A pharmacy manager explained, 
“We’re pretty in tune with what’s going on in our community as far as if somebody needs a 
support group or where to find that resource. Our patients have learned that they can come to us 
for anything.” Additionally, a few high-performing pharmacies used delivery drivers as a 
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mechanism for building relationships with patients. These pharmacies explained that delivery 
drivers are less intimidating to patients and may have an easier time building rapport with them.  
 Role of ties in implementation. Both high- and low-performing pharmacies described 
using their ties with patients to improve the quality of patient-pharmacist conversations about 
patients’ medication adherence and health outcomes. However, only high-performing 
pharmacies described using their ties with patients as a mechanism for engaging patients in 
medication management services and to spread the word about medication management services 
to their friends and family members. High-performing pharmacies explained that it was 
important to first build a relationship with a patient before introducing medication management 
services to patients to prevent patient resistance. Low-performing pharmacies, however, 
described making the mistake of trying to introduce medication management services to new 
patients with whom they had not established a relationship, leading to patient resistance.  
Maintenance of ties. Both high- and low-performing pharmacies discussed the 
importance of repeated interactions with patients; for example, making sure pharmacy staff ask 
about patients’ personal well-being and health each time they visit the pharmacy to build rapport 
over time. Both high- and low-performing pharmacies used patient engagement strategies to 
maintain ties with patients (e.g., motivational interviewing and getting caregivers involved) and 
pairing high-risk patients with a staff member to serve as their point of contact within the 
pharmacy. However, only high-performing pharmacies discussed the importance of developing a 
pharmacy climate that is supportive of patient engagement to ensure that the pharmacy builds 
strong relationships with all patients. To create such a climate, some pharmacy owners created 
reward systems for staff members who were able to engage hard-to-reach patients or developed 




In this study, we interviewed representatives from 40 community pharmacies that were 
participants in NC-CPESN to identify the role of network ties to support implementation of a 
community pharmacy enhanced services network, to describe how these ties are formed and 
maintained, and to compare these network ties among high- and low-performing pharmacies. We 
found that community pharmacies use numerous network ties to support implementation of 
medication management services including ties with healthcare providers and care managers, 
public health agencies, patients, and inter-personal ties of pharmacy staff. We also found that 
community pharmacies greatly vary in the experience with relationship building with other 
healthcare providers and patients, which may result in differential implementation quality of 
medication management programs. To our knowledge, this is the first study examining the 
network ties of community pharmacies participating in a team-based care model. There are 
similar studies examining relationships among healthcare providers and pharmacists in primary 
care, team-based care models33,34 but these studies focus on the healthcare provider-pharmacist 
dyad and do not look at other members of healthcare team (e.g., care managers, public health 
agencies, patients) or describe how these relationships are formed and maintained.  
The results from this study suggest that pre-existing relationships, repeated interactions, 
and multiple relationships (e.g., collaborating on two interventions) strengthen inter-
organizational partnerships over time—a finding replicated in other studies.41,66 For interventions 
that require pharmacies to coordinate care with other providers, it may be beneficial to assess 
pharmacies’ prior experience with inter-organizational partnerships and develop interventions to 
support pharmacies with less experience (e.g., creation of learning collaborative to disseminate 
effective organizational networking practices). Our findings also suggest that repeated 
interactions—such as scheduling regular meetings—and multiple relationships strengthened 
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relationships between pharmacies, providers, and care managers. Future studies could examine 
whether leveraging previous collaborations through interventions such as patient-centered 
medical homes improves implementation of future collaborations. Similar to another study, we 
found that many of the provider-pharmacist relationships were pharmacist initiated, which may 
limit inter-organizational relationship building. Collaboration across organizations may require 
more systematic efforts from both entities involved. Recent theories have hypothesized that 
inter-organizational partnerships may be facilitated by inter-organizational alignment or 
similarities in organizational values, characteristics, and support for implementation across 
partnering organizations.67 Future studies should test implementation strategies for developing 
organizational alignment across pharmacies, healthcare provider, and care management 
organizations for team-based care.  
Our findings suggest that partnerships among community pharmacists and care managers 
may be limited—even within team-based care models that include a care manager. In this study, 
some pharmacies, for example, did not consider care managers as a potential partner in 
delivering medication management services. Team-based care models assume that it is valuable 
to coordinate care with all types of providers; however, some organizational partners may not 
view certain healthcare providers as belonging to their network. Additional research could 
explore how pharmacies define the boundaries of their network and how these cognitions 
influence the structure of the pharmacy’s network (e.g., whether a pharmacy has ties with care 
managers or public health agencies). Studies of inter-organizational relationships have less 
commonly studied cognitions about social networks, such as how organization leaders define 
which individuals or organizations are a part of their network.66 The findings of this study 
suggest that leaders of high-performing pharmacies may have a broader definition of the 
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organizations included in their network since they used active strategies to build relationships not 
only with pharmacy organizations but also healthcare providers, care managers, and public 
health agencies.    
 Community pharmacies in our study used a wide variety of strategies to develop and 
maintain ties with patients. Since community pharmacies vary in the staff and resources available 
for implementation, it would be beneficial for future research to identify which patient 
engagement strategies might have the largest impact on enhanced service implementation 
effectiveness and for which settings and patient populations is the largest benefit observed. 
Findings from this study suggest that creation of formal policies may be an effective strategy for 
maintaining relationships with patients. Prior studies have shown that implementation policies 
and practices can influence an organization’s implementation climate (i.e., the extent to which an 
innovation is supported, rewarded, and expected).47,48,69 Therefore, future studies could examine 
how implementation policies and practices affect a pharmacy’s climate for patient-centered care 
and the pharmacy’s ability to build ties with patients.  
Limitations 
This study had several limitations. First, the interviews were conducted with community 
pharmacies and do not capture healthcare providers, care managers, or patients’ perspectives 
about their ties with community pharmacies. Future studies could employ network analysis 
methods to determine whether community pharmacies and their network ties have similar 
perspectives about their relationship quality. Second, this study examined implementation of 
enhanced services in North Carolina, the site of the first CPESN, and therefore findings from this 
study may not be generalizable to other states with less experience integrating community 
pharmacists into team-based care models. Third, the community pharmacies participating in NC-
CPESN and in this study are more likely to be independently owned rather than chain 
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pharmacies. Therefore, the findings from this study may not be representative of chain 
pharmacies. Independently owned pharmacies may have more flexibility to facilitate 
relationships with external organizations and with patients than chain pharmacies, which have a 
more formal organizational structure. Finally, participants’ responses during an interview can be 
influenced by how questions are phrased and participants’ comfort with the interview. To 
minimize risk of respondent bias, we used a community pharmacist as one of the co-facilitators 
and had a group of researchers and community pharmacists review the interview guide to ensure 
the questions would be easily interpreted.  
Conclusion  
 Community pharmacies are increasingly being integrated into team-based care models 
because they are highly accessible settings for delivering medication management services to 
patients who might otherwise be difficult to reach. Across settings, however, community 
pharmacies may vary in their ability to develop relationships with other healthcare providers and 
patients. As enhanced services interventions that require care coordination are scaled up and 
spread in community pharmacies in other states, additional research is needed to test 
implementation strategies that support community pharmacies with developing and maintaining 
relationships across a diverse group of stakeholders (e.g., healthcare providers, care managers, 





Table 5.1. Community pharmacy staff and site characteristics (n=40) 
 
Staff and Site Characteristics  Interviews 
% or Mean (SD) 
Staff Role  
   Pharmacy owner and pharmacist  
   Pharmacy manager and pharmacist 
   Pharmacist 







   0 to 3 years 
   4 to 5 years 





Pharmacy Performance  
   Low-performing pharmacy 




Pharmacy Setting  
   Single independent pharmacy 
   Multiple independent pharmacy 
   Chain pharmacy 






Total Full-Time Equivalent Pharmacist 2.6 (1.4) 
Total Full-Time Equivalent Pharmacy Technician 4.0 (2.5) 
Total Number of Staff (part-time and full-time) 12.5 (7.6) 
Weekly Prescription Volume  
   0 to 1,000  
   1,001 to 2,000 





Years in Operation 
   0 to 5 years 
   6 to 10 years 









Table 5.2. Differences in the role of network ties among high- and low-performing 
pharmacies  
 






   Gain awareness of NC-CPESN from leadership ties 
   Gain knowledge about NC-CPESN implementation 
from leadership ties  
Employee ties  
   Gain awareness of NC-CPESN from employee ties 
   Gain knowledge about NC-CPESN implementation 


















Ties with healthcare providers 
   Increase provider awareness of community pharmacy 
services 
   Increase provider knowledge of pharmacists’ clinical 
knowledge 
   Increase provider trust of community pharmacists 


















Boundary spanners  
   To learn about healthcare providers’ goals and 
priorities for patient care  
   Increase provider awareness of community pharmacy 
services 














Ties with care managers  
   Gain information about patients’ social needs 







Ties with public health agencies  
   Increase outreach to new patients  







Ties with patients  
   Facilitate conversations about medication adherence 
   Engage patients in medication management services    
   Ask patients to share information with family and 
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CHAPTER 6. STAGES OF CHANGE: MOVING COMMUNITY PHARMACIES FROM 
A DRUG DISPENSING TO POPULATION HEALTH MANAGEMENT MODEL  
Introduction 
 The aging of our population, the increasing prevalence of chronic illnesses, and the 
expansion of insurance coverage are expected to increase the demand for primary care in the 
next ten years.1-5 Patient complexity will also increase as the number of patients with multiple 
chronic conditions grows, requiring more time and resources from primary care.6,7 However, 
access to primary care providers (PCPs) is projected to be insufficient due to workforce 
shortages and uneven geographic distribution.1,2,8 To strengthen the capacity of the primary care 
system, innovative solutions are needed, including redistributing primary care functions to other 
healthcare team members.2,8  
Given their clinical training and accessibility, community pharmacists are well-positioned 
to support primary care, especially in providing medication management services.9-11 
Community pharmacists receive doctoral-level training that is increasingly focused on direct 
patient care, population health, and coordination with other healthcare professionals.12 In 
addition to training, community pharmacists are well-suited to support primary care because of 
their accessibility and frequent interactions with patients. Community pharmacies are 
geographically accessible to most patients; nearly 90% of the population lives within five miles 
of a community pharmacy.13,14 Community pharmacies also frequently interact with patients 
managing chronic conditions. A recent study, for example, found that Medicaid patients with 
multiple chronic conditions had ten times the annual visits to their community pharmacy 
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compared to their PCP (35 versus 3.5).15 Therefore, community pharmacies may be an ideal 
setting to deliver medication management services.  
 Over the past decade, community pharmacies have expanded their medication 
management services in response to healthcare reform and declining drug reimbursement 
margins.16-19 Community pharmacist-led medication management services have proven valuable 
by reducing medication errors, improving adherence, reducing hospital readmissions, and 
decreasing healthcare costs.20-27 Although their value has been demonstrated, these services have 
been underutilized in alternative payment primary care models.9,10 Part of the difficulty stems 
from the community pharmacy workflow, which is subject to frequent interruptions that can 
hinder implementation of medication management services.28-31 Additionally, payers and state 
regulations have limited community pharmacists’ ability to bill for medication management.9,32 
Given the small number of models in practice10,33,34, there is limited evidence on how to 
integrate community pharmacist-led medication management services into primary care 
delivery.35 Implementing these services requires community pharmacies to establish new 
relationships with PCPs and move from a drug dispensing to population health management 
model.36-39 Because population health management interventions often affect the entire 
organization rather than targeted units or departments, they require large-scale changes to care 
organization and delivery.36,38,39 Past studies of innovation implementation have tended to focus 
on interventions that affect a single dimension of an organization.40 Therefore, research is needed 
on how to implement large-scale organizational change40,41, particularly in community pharmacy 
settings where these interventions are being tested for the first time. To address this need, we 
examine the implementation process of community pharmacies in North Carolina participating in 




Our objectives are to: 1) compare implementation strategies of high- and low-performing 
community pharmacies at different stages of the innovation implementation process and 2) 
identify the implementation strategies that pharmacies use to sustain the innovation post-
implementation.  
Conceptual Framework 
Process models recognize a temporal order of implementation activities and can guide 
practitioners on how to implement innovations.42,43 Although there is diversity across process 
models (e.g., linear versus iterative), three stages are common across models: pre-
implementation, implementation, and sustainment.44-53 We chose Rogers’ Stages in the 
Innovation Process in Organizations because it has been applied to a wide variety of innovations 
and settings 44 and is well-suited for population health management interventions that require 
numerous organizational changes36,38,39 in response to innovation implementation.44  
Pre-implementation begins with the innovation-adoption process during which 
organizations identify the need for innovation (e.g., performance gap) and strategies that might 
meet the organization’s needs (“agenda-setting”) and is the right fit for the organization 
(“matching”).44 Organizations may identify the need for innovation by recognizing, and seeking 
innovations to address a problem (“problem-initiated approach”).44 More commonly, however, 
organizations become aware of an innovation and evaluate whether it could solve broader 
organizational problems (“innovation-initiated approach”).44 Metrics to assess fit include 
organizational capacity (e.g., resource and staff availability), staff and patient acceptability, and 
compatibility with the organization’s mission.44,48,50,54,55 Organizations might also consider 
aspects of the innovation itself—such as its complexity44,56, environmental context (e.g., external 
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funding, political climate, patient needs and resources), and adoption decisions of 
competitors.42,44,49,52,56  
The implementation stage begins once an organization decides to adopt an innovation. 
44,52 To prepare for implementation, the organization may change its structure including hiring 
and training personnel, purchasing equipment, and/or developing policies and procedures. 
44,46,52,54 Additionally, organizations go through a redefining process to adapt the innovation to its 
context and needs.44,57 Innovations can be adapted by changing the setting, mode of delivery, 
format or audience to achieve a better fit with the organization.57 After an organization has 
gained experience with implementation, it may refine its implementation process and scale the 
innovation within the organization; this is called the clarifying stage and may include increasing 
the number of patients receiving, or personnel involved in delivering, a service.44 The clarifying 
stage might also involve reflection and evaluation on the implementation process—such as the 
quality of implementation or whether the innovation is reaching its intended audience.48,50,52 
During sustainment, organizations focus on making the intervention a routine, sustainable 
part of the organization (i.e., the routinizing stage). An organization might allocate personnel 
permanently to be responsible for implementation, incorporate the innovation into the 
organizations’ standards or protocols, or devote part of the budget to implementation.47,50,52,54 
Within these three stages, practitioners may use different implementation strategies to 
support the implementation process. Implementation strategies are “methods or techniques used 
to enhance the adoption, implementation, and sustainability of a clinical program or practice.”58-
60 We have categorized implementation strategies using the following categories: plan, educate, 
restructure, quality-management, and finance strategies.58,59 Plan strategies assist organizations 
with gathering data about a problem, building buy-in among key stakeholders, initiating 
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leadership to support implementation, and developing relationships among implementation 
partners.58,59 Educate strategies are used to inform external and internal stakeholders about the 
intervention and processes for its implementation.58,59 Restructure strategies change the 
organization’s infrastructure to better support implementation (e.g., revising professional roles, 
hiring new personnel, or purchasing new equipment or technology).58,59 Notably, restructure 
strategies are not the same as the restructuring phase of implementation defined in Rogers’ 
model 44 and can be employed at different phases of the innovation process. Quality-management 
strategies facilitate performance monitoring, improvement, and evaluation by creating quality-
monitoring tools, systems, and processes for feedback.58,59 Finance strategies are used to create 
incentives and provide resources for implementation.58,59  
Methods 
Intervention Description 
The Community Pharmacy Enhanced Services Network (CPESNSM) is a national 
network of community pharmacies that have agreed to offer a set of medication management 
services.61 This study examines the North Carolina CPESN (NC-CPESN), the pioneer CPESN 
site.15 The NC-CPESN was launched in 2014 by the Community Care of North Carolina 
(CCNC)—the primary case management provider for NC Medicaid beneficiaries.15,62 NC-
CPESN not only requires community pharmacies to provide certain medication management 
services, but also holds pharmacies responsible for the outcomes of a defined patient population 
through value-based payment that is tailored to services based on patients’ risk score. 
Additionally, participating pharmacies must document their medication management services 
and patients’ clinical information in a web-based platform provided by CCNC. Patients include 
Medicaid, Medicare, and NC Health Choice beneficiaries as well as dual-eligible patients.  
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Selection of Study Sites   
  Because pharmacies could enroll at the beginning of the program year in 2014 (first year 
of the program), 2015, or 2016, they have varying levels of experience with NC-CPESN. 
Pharmacies in NC-CPESN also represent very different settings (e.g., independently-owned 
pharmacies, chain pharmacies, and federally-qualified outpatient pharmacies). To obtain diverse 
perspectives about implementation, we recruited 24 high- and 16 low-performing pharmacies on 
selected measures (e.g., medication adherence, emergency department utilization, hospital 
admissions, and total healthcare costs) (Figure 6.1).  
To recruit participants, we asked pharmacies to identify the individual in their pharmacy 
who was responsible for NC-CPESN implementation. We offered participants a $50 gift card for 
study participation. Five pharmacies declined to participate due to lack of time. Therefore, we 
asked study participants to suggest additional participants, and we were able to recruit an 
additional five community pharmacies. We stopped recruitment after 40 pharmacies when clear 
patterns began to emerge in the data (theme saturation).63 
Data Collection 
Two trained research assistants (KT and CR) conducted 40 semi-structured interviews 
(mean=51 minutes) from June – August 2017 to understand individual perspectives about NC-
CPESN implementation.64 The interview guide was based on Rogers’ theory.44 Interviews were 
conducted over the phone to facilitate participation across the State. The interviews were audio-
record and transcribed verbatim. Prior to beginning the interview, participants provided informed 
consent over the phone. The Institutional Review Board of the University of North Carolina at 
Chapel Hill approved this study (IRB # 17-1304). 
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Data Analysis  
 We used Dedoose (version 7.0) to generate a set of deductive codes based on Rogers’ 
theory 44,64 and the five categories of implementation strategies: plan, educate, restructure, 
quality-management, and finance.58,59 Two members of the research team (KT and CR) coded 
five transcripts to: determine how similarly codes were being applied; develop a set of inductive 
codes;64 and reach consensus on code definitions. The remaining transcripts were coded by one 
author (KT). After transcripts were coded, a summary was sent to five of the interview 
participants to confirm the findings; this member-checking process helps ensure that the 
interpretation is consistent with the experiences of study participants.65 Interview participants 
who were consulted agreed with the interpretation of the findings and did not suggest any 
modifications. We used the Consolidated Criteria for Reporting Qualitative Studies checklist to 
guide our reporting of qualitative methods and findings.66 
Results 
Sample Characteristics 
 Nearly half of 40 participants had a single role as a pharmacist (Table 6.1). Other 
participants occupied either dual roles as a pharmacy owner and pharmacist (20%), a pharmacy 
manager and pharmacist (17.5%), or a single role as a pharmacy technician (15%); 32.5% 
worked at their current pharmacy less than three years, 45% for 4-5 years, and 22.5% worked for 
six years or more. Participants came from multiple pharmacy settings including single 
independent pharmacies (20%), multiple independent pharmacies (50%), chain pharmacies 
(10%), and outpatient pharmacies including federally qualified health centers (20%). This 
distribution is similar to pharmacies participating in NC-CPESN.  
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Pre-implementation Stage: High-performing Pharmacies  
Agenda-setting. High-performing pharmacies discussed two planning implementation 
strategies to support the agenda-setting process: conducting site visits to other pharmacies to 
learn about their experiences with NC-CPESN, and conducting a local needs assessment to 
determine whether there was a need for NC-CPESN in the pharmacy (Table 6.2). During site 
visits, pharmacies gathered information about NC-CPESN, such as ease-of-implementation and 
the usability of the required documentation software. Pharmacies also evaluated whether NC-
CPESN would meet the needs of the pharmacy including patients’ needs, financial needs, and 
performance gaps. Pharmacies varied in the order these planning strategies were initiated. Some 
pharmacies first identified the need for innovation in their pharmacy and then conducted an 
environmental scan to identify potential solutions (“problem-initiated approach”). One pharmacy 
technician described her pharmacy’s process as, “We’re constantly looking for ways to improve 
our performance. Our clinical pharmacist was researching clinical services and came across NC-
CPESN.” Other pharmacies, through their employees’ social networks, leadership ties, and 
relationships with professional and academic organizations, learned about NC-CPESN and then 
determined whether NC-CPESN would meet the needs of their pharmacy (“innovation-initiated 
approach”). 
Matching. After identifying a need for NC-CPESN, pharmacies used three planning 
strategies to determine whether NC-CPESN was a good match for their pharmacy. Pharmacies 
first assessed their pharmacy’s readiness for NC-CPESN. Specifically, pharmacies assessed fit 
with the mission of the pharmacy (e.g., impact on patient care and outcomes) and whether their 
pharmacy had the organizational capacity to support NC-CPESN (e.g., staffing and resource 
availability, workspace). Second, pharmacies conducted local consensus discussions with 
external stakeholders (e.g., PCPs, care managers) and internal stakeholders (e.g., pharmacy 
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personnel) to obtain their buy-in. For external stakeholders, participants recommended 
discussing NC-CPESN’s purpose and identifying whether or not NC-CPESN would meet the 
needs of other healthcare providers’ patient population. For example, a pharmacy manager 
described assessing interest among PCPs: “We went to the providers that we already had a good 
relationship with and asked them if they would like to participate and whether it would be 
helpful for their patients.” For internal stakeholders, pharmacies discussed the importance of 
communicating information about NC-CPESN’s purpose, fit with the pharmacy’s mission, 
impact on staff roles and responsibilities, and implementation. Finally, participants identified 
both potential barriers to implementation (e.g., resistance among personnel and providers) and 
strategies for addressing challenges (e.g., including personnel in the implementation planning 
process).  
Pre-implementation Stage: Low-performing Pharmacies  
Agenda-setting. Unlike high-performing pharmacies, low-performing pharmacies did not 
visit other sites to learn about other pharmacies’ experiences with NC-CPESN or conduct a local 
needs assessment to determine whether the pharmacy had a need for NC-CPESN. As an 
example, one pharmacy manager described that her pharmacy did not assess whether NC-
CPESN met the needs of the pharmacy’s patient population prior to implementation. She 
explained, “We have a small percentage of Medicaid patients and thinking back on when we 
enrolled in the program, I don’t think we had the critical mass needed to justify this intervention 
and how much time we’ve spent on it.”  
Matching. Low-performing pharmacies also used planning strategies to determine 
whether NC-CPESN was a good match for their pharmacy. Low-performing pharmacies, for 
example, assessed whether NC-CPESN fit with the pharmacy’s mission and organizational 
capacity, such as a pharmacy management system that supports medication synchronization. 
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Low-performing pharmacies, however, failed to assess whether their pharmacy had sufficient 
staffing for NC-CPESN. Specifically, these pharmacies did not consider how much pharmacist 
time, outside of the time allotted to dispensing, would need to be dedicated to medication 
management services. Low-performing pharmacies also failed to identify potential 
implementation barriers (e.g., lack of patient engagement) and strategies for addressing those 
barriers, as well as failing to have local consensus discussions with external and internal 
stakeholders. One pharmacy owner, for example, explained that she did not engage her personnel 
prior to NC-CPESN implementation, which caused staff resistance to NC-CPESN. She 
explained,  
If I could go back, that’s something I’d change. Don’t wait until six months down the 
road, when you’ve already started the program, to tell them [personnel], this is what I 
want you to do. Because they won’t understand why you’re doing what you’re doing and 
they’ll be resistant. 
 
Implementation Stage: High-performing Pharmacies  
Restructuring. During implementation, participants from high-performing pharmacies 
discussed using planning and education implementation strategies to prepare for NC-CPESN. 
They developed a formal blueprint, recruited and designated personnel for implementation 
leadership positions, identified and prepared NC-CPESN champions, and pilot tested medication 
management services with a small number of patients and personnel. Pharmacies typically 
appointed pharmacists as implementation leaders responsible for developing implementation 
blueprints, training staff, and monitoring implementation efforts. Interestingly, pharmacies 
typically appointed pharmacy technicians to serve as champions for NC-CPESN including 
gaining buy-in for NC-CPESN among staff and patients and advocating for NC-CPESN within 
the pharmacy. To educate pharmacy personnel on NC-CPESN, some pharmacies used a train-
the-trainer approach, whereas others cross-trained multiple staff members on NC-CPESN 
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activities. Participants emphasized the importance of training personnel not only on the 
intervention, but also clinical training, especially for pharmacy technicians. 
Pharmacies used several strategies during the restructuring phase. They redefined job 
roles to include NC-CPESN activities, for example, appointing personnel to be responsible for 
recruiting patients for medication management services, delivering medication management 
services, or documenting services in the pharmacy’s management system. Some pharmacies 
hired new personnel to support NC-CPESN implementation—most commonly, clinical 
pharmacists and data entry specialists. Participants changed how they used their information 
systems to support NC-CPESN implementation, and they invested time into learning how to use 
the CCNC-provided software for documentation. Many pharmacies obtained advice from their 
software vendors on how to use their existing pharmacy management software alongside of the 
CCNC-provided software to support NC-CPESN implementation. One pharmacy owner said, 
“Whenever we start something new like NC-CPESN, we start with our software vendor. We 
explain what we are trying to implement, what we’d like the software to do, and ask them [the 
vendor] if it is possible.”  
A smaller number of high-performing pharmacies used quality-management strategies 
(e.g., developing and organizing quality-monitoring systems) to track performance data from 
their management system and share performance data with personnel (e.g., success stories and 
areas of improvement). Some pharmacies also developed posters, webinars, and report cards that 
visually compared current progress on performance measures.  
 Redefining. High-performing pharmacies used several planning strategies to adapt NC-
CPESN to the pharmacy’s local context. For example, pharmacies tailored the intervention to 
better meet patients’ needs including its setting (e.g., using a public location or provider’s office 
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for homeless patients requiring home services), the mode of delivery (e.g., using delivery drivers 
to collect patient information about medication adherence), and the cost (e.g., lowering patient 
fees for low-income patients). One pharmacist explained, “We started seeing a trend that we 
knew that our delivery drivers were our eyes and ears in the field. And it grew organically from 
there where we started using our drivers to support our adherence programs.” Participants also 
developed processes for prioritizing patients for medication management services such as using 
information collected during the patient encounter (e.g., availability of transportation, low 
literacy) in addition to risk.  
  High-performing pharmacies were more purposeful about establishing relationships with 
PCPs, care managers, and patients. Prior to adopting NC-CPESN, many participants engaged 
with PCPs by fax and very rarely interacted with CCNC care managers. With NC-CPESN, 
participants reported setting up face-to-face meetings with PCPs and care managers to discuss 
NC-CPESN overall as well as specific patient cases. Pharmacies used motivational interviewing 
techniques to build rapport with patients prior to introducing medication management services to 
them. Additionally, participants collaborated with PCPs and care managers to engage hard-to-
reach patients. One pharmacy manager explained, “We have some patients that receive 
information better from their medical providers than from pharmacy staff. So we’ll call the 
physician and get them to reinforce what we’ve recommended to the patient.”   
Clarifying. Participants from high-performing pharmacies expanded medication 
management services using planning (e.g., staging implementation scale-up) and education (e.g., 
creating and distributing materials) strategies. They planned an implementation scale-up by 
enhancing outreach to recruit additional patients, increasing the number of personnel involved in 
service delivery, and partnering with community-based organizations, such as local agencies for 
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aging services and public housing authorities. Additionally, pharmacies developed and 
distributed educational materials to patients including flyers, brochures, and tags stapled to 
prescription bags.  
Pharmacies also adjusted their implementation processes after gaining experience with 
NC-CPESN. They used restructuring strategies such as redefining professional roles based on 
experiences with implementation. For example, pharmacies matched hard-to-reach patients with 
a staff member who successfully engaged them. Some pharmacies also employed quality-
management strategies such as purposefully reexamining implementation to determine if their 
pharmacy’s processes should be adjusted or if certain medication management services should be 
de-implemented. As an example, some pharmacies had to build in more time for developing care 
plans for complex patients. One pharmacist explained,  
We have really gotten more complex patients than what we were getting at the beginning 
[of NC-CPESN], people that are on 12 to 15 medicines, people that are in and out of the 
hospital. When we started to evaluate our process and workflow, we realized we needed 
to set aside more time for these patients. 
 
Implementation Stage: Low-performing Pharmacies  
Restructuring. Low-performing pharmacies used many of the same planning strategies as 
high-performing pharmacies but executed them differently. For example, when developing an 
implementation blueprint, low-performing pharmacies included details on how to deliver 
medication services but unlike high-performers, did not include a procedure for documentation. 
As a result, services were inadequately documented for reimbursement requirements and caused 
confusion about which services a patient had received; sometimes documentation had too much 
detail, leading to pharmacies seeing fewer patients due to time constraints. Low-performing 
pharmacies were less likely to use planning strategies such as piloting medication management 
services, which caused problems with implementation (e.g., mismatch between the number of 
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patients and staffing capacity). Additionally, low-performing pharmacies failed to appoint local 
champions and/or designate implementation leaders—resulting in confusion about who was 
responsible for leading implementation. 
Low-performing pharmacies experienced challenges with education (e.g., training 
personnel) and restructuring (e.g., redefining professional roles) strategies. They described either 
failing to train personnel prior to implementation or including insufficient detail in staff training. 
One pharmacy technician said, “I was just thrown in the water, sink or swim, with very little 
training. I did a lot of it incorrectly and wasted a lot of time and became very frustrated.” 
Similarly, low-performing pharmacies reported either failing to redefine professional roles or 
redefining professional roles in a way that hindered implementation. For example, some 
pharmacies designated only one pharmacist to be responsible for NC-CPESN-related activities, 
resulting in burnout for some staff members. None of the low-performing pharmacies reported 
using quality-management strategies.   
Redefining. Low-performing pharmacies used some of the planning and finance strategies 
as high performing pharmacies (e.g., tailoring intervention to patients’ needs, reducing patient 
fees); however, they failed to develop relationships with PCPs, care managers, and patients. 
Some low-performing pharmacies introduced medication management services without first 
building relationships with individual patients, causing patient resistance. Others introduced too 
many services to a patient at a time—causing the patient to become overwhelmed and resistant to 
enrolling in medication management services. Similarly, participants described trying to request 
patient health information from providers without first building a relationship, resulting in 
resistance from the provider to share patient information. Low-performing pharmacies also 
described failing to reach out to care managers: “We haven’t really worked with them [care 
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managers]. It would probably be beneficial but in the day-to-day we barely have a minute to step 
away from the counter.”  
Clarifying. Similar to high-performing pharmacies, low-performing pharmacies used 
planning strategies to scale up implementation and education strategies to introduce medication 
management services. Where high- and low- performers differed was the use of restructuring and 
quality-management strategies. High-performing pharmacies described being purposeful in 
ensuring that professional roles were defined, for example, using pharmacists and pharmacy 
technicians at the top of their license. Low-performing pharmacies described failing to use 
pharmacist and pharmacy technicians at the top of their license—causing inefficiency and 
assigning too much work to the pharmacist. Low-performing pharmacies also described not 
taking the time to assess implementation quality and make adjustments to the process—resulting 
in continued poor quality implementation. For example, one pharmacist stated: “We had a lot of 
enthusiasm at the beginning [of NC-CPESN] from everyone and then that sort of waned. 
Thinking back, we should have checked the temperature of things and maybe changed course to 
reenergize our staff.” 
Sustainment Stage 
Routinizing. Although all pharmacies reached the implementation stage, a smaller group 
(all high-performing) of pharmacies had reached a sustainment stage. These pharmacies 
discussed planning strategies such as obtaining formal commitments and developing resource-
sharing agreements with PCPs (e.g., collaborative practice agreements, gaining electronic health 
record (EHR) access). Pharmacies also integrated medication management services into 
personnel policies (e.g., hiring and performance evaluation processes and new staff orientation) 
and created incentives for employee participation in NC-CPESN. Pharmacies that were part of a 
larger organization (e.g., multiple-independent pharmacies) used quality-management strategies 
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such as creating centralized support systems for pharmacy personnel implementing NC-CPESN, 
for example, hiring centralized pharmacists to assist local pharmacies with recruiting patients for 
medication management services.  
Pharmacies that had reached the routinizing stage also described realizing benefits from 
NC-CPESN participation, such as recruiting new patients, gaining confidence in their clinical 
skills, and getting providers and patients accustomed to pharmacists’ role in patient care. One 
pharmacist described, “We’ve seen a change in working with providers. In the beginning they 
were like, ‘Why are you asking about my patients?’ But now, they’re are actually coming to the 
pharmacy and asking for our advice.” Pharmacies that had realized benefits from NC-CPESN 
indicated that their pharmacy intended to sustain medication management services beyond the 
NC-CPESN grant program. Pharmacies that had not yet realized benefits from the program were 
more uncertain about whether medication management services would be sustained in their 
pharmacy.  
Discussion 
 We interviewed representatives from 40 community pharmacies that were implementing 
NC-CPESN, a complex Medicaid population health management intervention, to compare 
implementation strategies of high- and low-performing pharmacies within stages of 
implementation and to identify the strategies used to sustain the intervention. Similar to other 
complex healthcare innovations, implementation of NC-CPESN required multiple 
implementation strategies (e.g., plan, educate, restructure, quality management, finance) to 
support the implementation process58,59,67 Different strategies were needed at different stages of 
implementation and some strategies were repeated and refined throughout the implementation 
process.69 Findings also revealed that (1) high- and low-performing pharmacies relied on some of 
the same implementation strategies but employed them differently and (2) high-performing 
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pharmacies employed some strategies that low-performing pharmacies did not employ—both of 
which contributed to differential quality implementation of NC-CPESN. We are aware of no 
previous studies that have identified and compared implementation strategies employed in 
community pharmacy programs. A similar study has been conducted in primary care but did not 
track strategies across different stages of implementation.68 
Participants used a wide variety of implementation strategies to support community 
pharmacy medication management services. For example, pharmacies used a number of 
education strategies to increase individual patients’ awareness of community pharmacy services, 
but continued to encounter resistance from some patients—a finding that is consistent with other 
studies.30,31,69 Future studies could examine population-level, education strategies (e.g., media 
campaigns) on awareness and acceptability of community pharmacist-led medication 
management services by patients and their caregivers. Similar to other medication management 
interventions70-72, pharmacies used restructuring strategies, including redefining the professional 
roles of pharmacists, pharmacy technicians, and other pharmacy personnel. Past studies have 
shown that, with training, pharmacy technicians can support medication management activities 
by gathering patient information and documenting medication histories.73-75 Future studies 
should test the effectiveness of restructuring strategies that delegate components of population 
health management interventions to non-pharmacist personnel.  
Although high- and low-performing pharmacies utilized many of the same strategies, 
their approach varied, resulting in different implementation outcomes (e.g., acceptability among 
personnel and efficiency).76 To better understand variation in implementation, future studies 
could document a small set of implementation strategies in detail and compare how the 
implementation strategies are employed across high- and low-performing pharmacies. Future 
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work could use existing guidelines for implementation documentation to describe the actors 
involved with carrying out an implementation strategy, why one implementation strategy was 
chosen over another (i.e., justification), and the frequency and length of time an implementation 
strategy was used (i.e., dosage).60,77 Future research could also examine which core components 
of implementation strategies are associated with effective implementation of medication 
management interventions.59  
We also found that low-performing pharmacies omitted certain implementation strategies 
used by high-performing pharmacies and were less likely to progress to later stages of 
implementation (i.e., routinizing stage), suggesting that some strategies may have a bigger 
impact on implementation effectiveness. For example, low-performing pharmacies did not use 
quality-monitoring strategies and failed to assess whether there was a need for NC-CPESN in 
their pharmacy (e.g., sufficient number of Medicaid patients). Determining early on whether the 
innovation is a good match for the organization is critical for sustainability78 but often gets 
neglected in implementation research.49,79 Future studies could tailor existing tools for tracking 
implementation progress and milestones, such as the Stages of Implementation Completion 
measure46,80, to community pharmacy settings. Such studies could examine whether reaching 
certain stages of implementation or achieving specific implementation milestones (e.g., enrolling 
a certain number of patients in medication management services) impact program performance 
and sustainability.   
Limitations 
 This study had several limitations. First, although the interview guide was informed by 
Rogers’ theory, we may have neglected other factors that affect implementation (e.g., external 
factors such as reimbursement policies and availability of PCPs). Second, we used a qualitative 
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approach to assigning community pharmacies to different stages of the implementation process 
based on subjective information provided by participants during an interview. Future studies 
could develop more objective measures, such as checklists, to assign community pharmacies to 
different phases of implementation for population health management interventions.46,80 Third, 
our study examined the implementation strategies employed by the pharmacies (e.g., delivery 
system) and did not examine strategies used other actors involved in the implementation process 
such as the developer of NC-CPESN, CCNC (e.g., support system).81 Future studies could 
examine the implementation strategies used by systems that provide support to community 
pharmacies implementing population health management interventions. Finally, because our aim 
was to capture the breadth of implementation strategies used by community pharmacies to 
implement a complex intervention, our study did not document implementation strategies in 
sufficient depth for replication.60  
Conclusion 
 Community pharmacies nationwide are increasingly delivering medication management 
services under alternative payment models seeking to improve population health. In the process, 
these models may redefine how community pharmacies collaborate with other healthcare 
providers and patients. Since these collaborations are relatively new to healthcare, continued 
research is needed to identify how to effectively implement community pharmacist-led 
medication management services in collaboration with other members of the healthcare team. As 
the healthcare system moves toward greater collaboration across otherwise disparate providers, 
there is also the need to better understand how to implement complex innovations that require 
simultaneous changes to many facets of a healthcare organization. This study contributes to the 
understanding of complex innovation implementation by identifying and comparing the 

















 Based on program year 
and performance  
 
Year 1 pharmacies (n=15) 
 High performing (n=8) 
 Low performing (n=7) 
 
Year 2 pharmacies (n=13) 
 High performing (n=7) 
 Low performing (n=6) 
 
Year 3 pharmacies (n=12) 
 High performing (n=9) 
 Low performing (n=3) 
 
Excluded (n=5) 








Table 6.1. Community pharmacy staff and site characteristics (n=40) 
 
Staff and Site Characteristics  Interviews 
%  
Staff Role  
   Pharmacy owner and pharmacist  
   Pharmacy manager and pharmacist 
   Pharmacist 







  0 to 3 years 
  4 to 5 years 





Pharmacy Setting  
   Single independent pharmacy 
   Multiple independent pharmacy 
   Chain pharmacy 






Year of Program Enrollment 
   Year 1  
   Year 2 





Pharmacy Performance  
   Low-performing pharmacy 


























 (+) Visit other sites to gather information 
about NC-CPESN implementation and 
perceived benefits of NC-CPESN 
(+) Conduct a local needs assessment to 
determine whether there is a need for NC-




 (-) Visit other sites to gather information 
about NC-CPESN implementation and 
perceived benefits of NC-CPESN 
(-) Conduct a local needs assessment to 
determine whether there is a need for NC-





(+) Assess for readiness including staffing, 
resources, and mission fit  
(+) Conduct local consensus discussions 
among external and internal stakeholders 
(+) Identify potential barriers and strategies 




(+) Assess for readiness including resources 
and mission fit  
(-) Assess readiness including staffing 
(-) Conduct local consensus discussions 
among external and internal stakeholders 
(-) Identify potential barriers and strategies 


























(+) Develop a formal implementation 
blueprint for service delivery and 
documentation 
(+) Recruit and designate for leadership 
(+) Identify and prepare champions 




Educate strategies    
 (+) Conduct training with personnel via train-
the-trainer or cross-training approaches 
 
Restructure strategies 
(+) Revise professional roles and hire new 
personnel 
(+) Change record systems  
 
Quality-management strategies 





(+) Develop a formal implementation 
blueprint for service delivery 
(-) Develop a formal implementation 
blueprint for documentation 
(-) Recruit and designate for leadership 
(-) Identify and prepare champions 
(-) Pilot test medication management 
services  
 
Educate strategies    
(+) Conduct training with personnel via 
train-the-trainer or cross-training approaches 
 
Restructure strategies 
(+) Revise professional roles and hire new 
personnel 
(+) Change record systems  
 
Quality-management strategies 
(-) Develop and organize quality-monitoring 
systems  
Redefining 
Plan strategies  
(+) Tailor strategies to overcome barriers and 
honor preferences  
(+) Develop relationships with PCPs, care 




Plan strategies  
(+) Tailor strategies to overcome barriers 
and honor preferences  
 (-) Develop relationships with PCPs, care 





(+) Reduce patient fees for low-income 
patients 
 





(+) Stage implementation scale up   
 
Educate strategies 




(+) Revise professional roles based on 
experience with implementation (e.g., using 
pharmacist and pharmacy technicians at the 
top of their license) 
 
Quality-management strategies 
(+) Purposefully reexamine implementation 
and decide whether to continue, adjust 




(+) Stage implementation scale up   
 
Educate strategies 




(-) Revise professional roles based on 
experience with implementation (e.g., using 
pharmacist and pharmacy technicians at the 
top of their license) 
 
Quality-management strategies 
(-) Purposefully reexamine implementation 
and decide whether to continue, adjust 









(+) Obtain formal commitments  
(+) Develop resource sharing agreements  
 
Quality-management strategies 
(+) Create centralized support systems for 
pharmacy personnel implementing NC-
CPESN 
 
Restructure strategies  
Revise professional roles in personnel policies 
to include NC-CPESN implementation (e.g., 
hiring, new staff orientation) 
 
Finance strategies 
Alter incentive structure for employee 





Not applicable. (None of the low-performing 
pharmacies reached the routinizing stage).  





1. Bodenheimer T, Pham HH. Primary care: current problems and proposed solutions. 
Health Aff (Millwood). 2010;29(5):799-805. 
2. Ghorob A, Bodenheimer T. Sharing the care to improve access to primary care. The New 
England journal of medicine. 2012;366(21):1955-1957. 
3. Ward BW, Schiller JS, Goodman RA. Multiple chronic conditions among US adults: a 
2012 update. Prev Chronic Dis. 2014;11:E62. 
4. Anderson LA, Goodman RA, Holtzman D, Posner SF, Northridge ME. Aging in the 
United States: opportunities and challenges for public health. American journal of public 
health. 2012;102(3):393-395. 
5. Dall TM, Gallo PD, Chakrabarti R, West T, Semilla AP, Storm MV. An aging population 
and growing disease burden will require a large and specialized health care workforce by 
2025. Health Aff (Millwood). 2013;32(11):2013-2020. 
6. Bodenheimer T, Chen E, Bennett HD. Confronting the growing burden of chronic 
disease: can the U.S. health care workforce do the job? Health Aff (Millwood). 
2009;28(1):64-74. 
7. Shulman LN, Jacobs LA, Greenfield S, et al. Cancer care and cancer survivorship care in 
the United States: will we be able to care for these patients in the future? J Oncol Pract. 
2009;5(3):119-123. 
8. Green LV, Savin S, Lu Y. Primary care physician shortages could be eliminated through 
use of teams, nonphysicians, and electronic communication. Health Aff (Millwood). 
2013;32(1):11-19. 
9. Smith M, Bates DW, Bodenheimer TS. Pharmacists belong in accountable care 
organizations and integrated care teams. Health Aff (Millwood). 2013;32(11):1963-1970. 
10. Smith M, Bates DW, Bodenheimer T, Cleary PD. Why pharmacists belong in the medical 
home. Health Aff (Millwood). 2010;29(5):906-913. 
11. Kennedy AG, Chen H, Corriveau M, MacLean CD. Improving population management 
through pharmacist-primary care integration: a pilot study. Popul Health Manag. 
2015;18(1):23-29. 
12. Saseen JJ, Ripley TL, Bondi D, et al. ACCP Clinical Pharmacist Competencies. 
Pharmacotherapy. 2017;37(5):630-636. 
13. CDC. Creating Community-Clinical Linkages Between Community Pharmacists and 
Physicians. Atlanta, GA2017. 
 
111 
14. NACDS. National Association of Chain Drug Stores Health Care Workshop, Project No. 
P131207. 2014; http://www.nacds.org/ceo/2014/0508/supplemental_comments.pdf. 
Accessed October 10, 2017. 
15. CCNC. Community Pharmacy Enhanced Services Network. 2016; 
https://www.communitycarenc.org/population-management/pharmacy/community-
pharmacy-enhanced-services-network-cpesn/. Accessed October 21, 2016. 
16. Colla CH, Lewis VA, Beaulieu-Jones BR, Morden NE. Role of pharmacy services in 
accountable care organizations. J Manag Care Spec Pharm. 2015;21(4):338-344. 
17. Doucette WR, Kreling DH, Schommer JC, Gaither CA, Mott DA, Pedersen CA. 
Evaluation of community pharmacy service mix: evidence from the 2004 National 
Pharmacist Workforce Study. Journal of the American Pharmacists Association : JAPhA. 
2006;46(3):348-355. 
18. Doucette WR, Rippe JJ, Gaither CA, Kreling DH, Mott DA, Schommer JC. Influences on 
the frequency and type of community pharmacy services. Journal of the American 
Pharmacists Association : JAPhA. 2017;57(1):72-76.e71. 
19. Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 
years of experience in a large integrated health care system. Journal of managed care 
pharmacy : JMCP. 2010;16(3):185-195. 
20. Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of a community pharmacist 
intervention in diabetes care: a randomized controlled trial. J Clin Pharm Ther. 
2011;36(5):602-613. 
21. Messerli M, Blozik E, Vriends N, Hersberger KE. Impact of a community pharmacist-led 
medication review on medicines use in patients on polypharmacy--a prospective 
randomised controlled trial. BMC health services research. 2016;16:145. 
22. Ottenbros S, Teichert M, de Groot R, et al. Pharmacist-led intervention study to improve 
drug therapy in asthma and COPD patients. Int J Clin Pharm. 2014;36(2):336-344. 
23. Blalock SJ, Roberts AW, Lauffenburger JC, Thompson T, O'Connor SK. The effect of 
community pharmacy-based interventions on patient health outcomes: a systematic 
review. Med Care Res Rev. 2013;70(3):235-266. 
24. Brown TJ, Todd A, O'Malley C, et al. Community pharmacy-delivered interventions for 
public health priorities: a systematic review of interventions for alcohol reduction, 
smoking cessation and weight management, including meta-analysis for smoking 
cessation. BMJ Open. 2016;6(2):e009828. 
25. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by 
community pharmacists to improve patient adherence to chronic medication: a systematic 
review. The Annals of pharmacotherapy. 2005;39(2):319-328. 
 
112 
26. Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management 
interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern 
Med. 2015;175(1):76-87. 
27. Smith M, Giuliano MR, Starkowski MP. In Connecticut: improving patient medication 
management in primary care. Health Aff (Millwood). 2011;30(4):646-654. 
28. Szeinbach S, Seoane-Vazquez E, Parekh A, Herderick M. Dispensing errors in 
community pharmacy: perceived influence of sociotechnical factors. Int J Qual Health 
Care. 2007;19(4):203-209. 
29. Hoxsie DM, Keller AE, Armstrong EP. Analysis of community pharmacy workflow 
processes in preventing dispensing errors. Journal of Pharmacy Practice. 
2006;19(2):124-130. 
30. Snyder ME, Earl TR, Gilchrist S, et al. Collaborative drug therapy management: case 
studies of three community-based models of care. Prev Chronic Dis. 2015;12:E39. 
31. Oladapo AO, Rascati KL. Review of survey articles regarding medication therapy 
management (MTM) services/programs in the United States. J Pharm Pract. 
2012;25(4):457-470. 
32. Maine LL, Knapp KK, Scheckelhoff DJ. Pharmacists and technicians can enhance patient 
care even more once national policies, practices, and priorities are aligned. Health Aff 
(Millwood). 2013;32(11):1956-1962. 
33. Urick B, Brown P, Easter JC. Achieving Better Quality and Lower Costs in Medicaid 
Through Enhanced Pharmacy Services. N C Med J. 2017;78(3):188-189. 
34. Farley JF, Ferreri SP, Easter JC, McClurg MR. The North Carolina Experiment: Active 
Research in the Development and Assessment of New Practice Models. N C Med J. 
2017;78(3):186-190. 
35. Smith MG, Ferreri SP, Brown P, Wines K, Shea CM, Pfeiffenberger TM. Implementing 
an integrated care management program in community pharmacies: A focus on 
medication management services. Journal of the American Pharmacists Association : 
JAPhA. 2017;57(2):229-235.e221. 
36. Steenkamer BM, Drewes HW, Heijink R, Baan CA, Struijs JN. Defining Population 
Health Management: A Scoping Review of the Literature. Popul Health Manag. 
2017;20(1):74-85. 
37. Hibbard JH, Greene J, Sacks RM, Overton V, Parrotta C. Improving Population Health 
Management Strategies: Identifying Patients Who Are More Likely to Be Users of 
Avoidable Costly Care and Those More Likely to Develop a New Chronic Disease. 
Health services research. 2017;52(4):1297-1309. 
 
113 
38. McCarthy, D., Klein S, Cohen A. The road to accountable care: building systems for 
population health management. Washington DC2014. 
39. Felt-Lisk SHT. Exploring the Promise of Population Health Management to Programs to 
Improve Health. Washington DC2011. 
40. Lee SY, Weiner BJ, Harrison MI, Belden CM. Organizational transformation: a 
systematic review of empirical research in health care and other industries. Med Care Res 
Rev. 2013;70(2):115-142. 
41. Best A, Greenhalgh T, Lewis S, Saul JE, Carroll S, Bitz J. Large-system transformation 
in health care: a realist review. The Milbank quarterly. 2012;90(3):421-456. 
42. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering 
implementation of health services research findings into practice: a consolidated 
framework for advancing implementation science. Implementation science : IS. 
2009;4:50. 
43. Nilsen P. Making sense of implementation theories, models and frameworks. 
Implementation science : IS. 2015;10:53. 
44. Rogers EM. Diffusion of innovations. New York City, NY: Simon and Schuster; 2010. 
45. CIHR. About knowledge translation. 2016; http://www.cihr-irsc.gc.ca/e/29418.html. 
Accessed September 7, 2017. 
46. Chamberlain P, Brown CH, Saldana L. Observational measure of implementation 
progress in community based settings: the Stages of Implementation Completion (SIC). 
Implementation science : IS. 2011;6:116. 
47. Bergh AM, Arsalo I, Malan AF, Patrick M, Pattinson RC, Phillips N. Measuring 
implementation progress in kangaroo mother care. Acta Paediatr. 2005;94(8):1102-1108. 
48. Meyers DC, Durlak JA, Wandersman A. The quality implementation framework: a 
synthesis of critical steps in the implementation process. Am J Community Psychol. 
2012;50(3-4):462-480. 
49. Aarons GA, Hurlburt M, Horwitz SM. Advancing a conceptual model of evidence-based 
practice implementation in public service sectors. Adm Policy Ment Health. 
2011;38(1):4-23. 
50. Davis SM, Peterson JC, Helfrich CD, Cunningham-Sabo L. Introduction and conceptual 
model for utilization of prevention research. American journal of preventive medicine. 
2007;33(1 Suppl):S1-5. 
51. Wilson KM, Brady TJ, Lesesne C, Translation NWGo. An organizing framework for 




52. Fixsen DL, Naoom SF, Blase KA, Friedman RM, Wallace F. Implementation research: a 
synthesis of the literature. Tampa, FL2005. 
53. Ettlie JE. Adequacy of stage models for decisions on adoption of innovation. 
Psychological Reports. 1980;46(3):991-995. 
54. Helfrich CD, Savitz LA, Swiger KD, Weiner BJ. Adoption and implementation of 
mandated diabetes registries by community health centers. American journal of 
preventive medicine. 2007;33(1 Suppl):S50-58; quiz S59-65. 
55. Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three newly 
developed implementation outcome measures. Implementation science : IS. 
2017;12(1):108. 
56. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations 
in service organizations: systematic review and recommendations. The Milbank 
quarterly. 2004;82(4):581-629. 
57. Stirman SW, Miller CJ, Toder K, Calloway A. Development of a framework and coding 
system for modifications and adaptations of evidence-based interventions. 
Implementation science : IS. 2013;8:65. 
58. Powell BJ, McMillen JC, Proctor EK, et al. A compilation of strategies for implementing 
clinical innovations in health and mental health. Med Care Res Rev. 2012;69(2):123-157. 
59. Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation 
strategies: results from the Expert Recommendations for Implementing Change (ERIC) 
project. Implementation science : IS. 2015;10:21. 
60. Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for 
specifying and reporting. Implementation science : IS. 2013;8:139. 
61. CPESN-USA. What is CPESN? 2017; https://www.cpesn.com/what-is-cpesn/. Accessed 
September 11, 2017. 
62. CCNC. Community Care of North Carolina: A history. 2017; 
https://www.communitycarenc.org/about-us/history-ccnc-rev/. Accessed September 11, 
2017. 
63. Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with 
data saturation and variability. Field methods. 2006;18(1). 
64. Ulin PR, Robinson ET, Tolley EE. Qualitative methods in public health. 1st Edition ed. 
San Francisco, CA: Josey-Bass; 2004. 




66. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 
2007;19(6):349-357. 
67. Magnabosco JL. Innovations in mental health services implementation: a report on state-
level data from the U.S. Evidence-Based Practices Project. Implementation science : IS. 
2006;1:13. 
68. Hysong SJ, Best RG, Pugh JA. Clinical practice guideline implementation strategy 
patterns in Veterans Affairs primary care clinics. Health services research. 2007;42(1 Pt 
1):84-103. 
69. Law AV, Okamoto MP, Brock K. Ready, willing, and able to provide MTM services?: A 
survey of community pharmacists in the USA. Res Social Adm Pharm. 2009;5(4):376-
381. 
70. Myers CE. Opportunities and challenges related to pharmacy technicians in supporting 
optimal pharmacy practice models in health systems. American journal of health-system 
pharmacy : AJHP : official journal of the American Society of Health-System 
Pharmacists. 2011;68(12):1128-1136. 
71. Benavides S, Rambaran KA. Pharmacy technicians: Expanding role with uniform 
expectations, education and limits in scope of practice. J Res Pharm Pract. 
2013;2(4):135-137. 
72. Schultz JM, Jeter CK, Martin NM, Mundy TK, Reichard JS, Van Cura JD. ASHP 
Statement on the Roles of Pharmacy Technicians. American journal of health-system 
pharmacy : AJHP : official journal of the American Society of Health-System 
Pharmacists. 2016;73(12):928-930. 
73. Buck TC, Gronkjaer LS, Duckert ML, Rosholm JU, Aagaard L. Medication 
reconciliation and prescribing reviews by pharmacy technicians in a geriatric ward. J Res 
Pharm Pract. 2013;2(4):145-150. 
74. Sen S, Siemianowski L, Murphy M, McAllister SC. Implementation of a pharmacy 
technician-centered medication reconciliation program at an urban teaching medical 
center. American journal of health-system pharmacy : AJHP : official journal of the 
American Society of Health-System Pharmacists. 2014;71(1):51-56. 
75. Cooper JB, Lilliston M, Brooks D, Swords B. Experience with a pharmacy technician 
medication history program. American journal of health-system pharmacy : AJHP : 
official journal of the American Society of Health-System Pharmacists. 
2014;71(18):1567-1574. 
76. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: 




77. Bunger AC, Powell BJ, Robertson HA, MacDowell H, Birken SA, Shea C. Tracking 
implementation strategies: a description of a practical approach and early findings. 
Health research policy and systems / BioMed Central. 2017;15(1):15. 
78. Wiltsey Stirman S, Kimberly J, Cook N, Calloway A, Castro F, Charns M. The 
sustainability of new programs and innovations: a review of the empirical literature and 
recommendations for future research. Implementation science : IS. 2012;7:17. 
79. Wisdom JP, Chor KH, Hoagwood KE, Horwitz SM. Innovation adoption: a review of 
theories and constructs. Adm Policy Ment Health. 2014;41(4):480-502. 
80. Saldana L, Chamberlain P, Wang W, Hendricks Brown C. Predicting program start-up 
using the stages of implementation measure. Adm Policy Ment Health. 2012;39(6):419-
425. 
81. Leeman J, Birken SA, Powell BJ, Rohweder C, Shea CM. Beyond "implementation 
strategies": classifying the full range of strategies used in implementation science and 
practice. Implementation science : IS. 2017;12(1):125. 
 
117 
CHAPTER 7. SUMMARY OF FINDINGS AND IMPLICATIONS FOR POLICY, 
PRACTICE, AND RESEARCH 
Summary of Findings 
 The purpose of this research was to explore the determinants of implementation 
effectiveness of a community pharmacy population health management program for Medicaid 
beneficiaries. In the first study, we examined the organizational determinants of implementation 
effectiveness using the organizational theory of innovation implementation.1,2 In the second 
study, we identified and compared the use of network ties to support implementation among 
high- and low-performing community pharmacies. In the third study, we identified and compared 
the implementation strategies used at different stages of the innovation process among high- and 
low-performing community pharmacies using the Rogers’ stages of the innovation process in 
organizations.4  
 The first study quantitatively tested the organizational theory of innovation 
implementation, which has only been tested in a few other studies and never tested in a 
community pharmacy setting.1,2,5,6 In this study, we found that key constructs from this theory 
(e.g., implementation climate, innovation-values fit) were positively associated with 
implementation effectiveness including implementation activity and program reach. 
Additionally, we found evidence that innovation-values fit moderated the effect of 
implementation climate on implementation effectiveness, which has not been tested previously. 
This study contributes to the literature by confirming the relationships hypothesized in this 
theory and demonstrating that this theory has relevance for community pharmacy settings.  
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 The second study qualitatively explored the use of network ties to support 
implementation of a population health management program. Previous studies have examined 
pharmacist-provider relationships in primary care population health management programs33,34 
but have not examined these relationships in community pharmacy settings. We found key 
differences in how high- and low-performing pharmacies managed relationships with external 
organizations including healthcare providers, care managers, public health agencies, and patients. 
High-performing pharmacies, for example, had a broader network of ties with healthcare 
providers, care managers, and public health agencies whereas low-performing pharmacies had 
not formed such relationships. High-performing pharmacies also described using strategies to 
maintain relationships with healthcare providers outside of standard communication about 
patients, such as creating boundary-spanning positions within their pharmacy (e.g., having their 
pharmacist work in a primary care practice one day a week) to learn more about physicians’ 
needs for medication management services. Both high- and low-performing pharmacies used a 
number of strategies to building relationships with patients including appointing staff members 
to engage specific high-risk patients and learning more about resources in the local community to 
assist patients’ with social needs such as housing or utility assistance.  
The third study qualitatively explored the implementation process used by community 
pharmacies to implement a Medicaid medication management intervention using Rogers’ 
theory4, which has not been studied previously. We found that community pharmacies employed 
a number of implementation strategies such as redefining job responsibilities to ensure 
pharmacists and pharmacy technicians are working at the top of their license. Findings also 
revealed differences in the implementation process among high- and low-performing 
pharmacies. High-performing pharmacies, for example, were more likely to reach later stages of 
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implementation and used strategies such as establishing collaborative practice agreements with 
providers and gaining EHR access. Low-performing pharmacies were less likely to gain 
stakeholder buy-in prior to implementation, resulting in staff resistance to change.    
Practice Implications 
 The main findings from this dissertation were that organizational determinants (e.g., 
implementation climate and innovation-values fit), relationship building with other healthcare 
providers and patients, and the implementation process affected implementation effectiveness of 
a population health management program in community pharmacies. The findings from the first 
study suggest that community pharmacies may need assistance with developing a supportive 
implementation climate for medication management programs. Pharmacies, for example, may 
need leadership training on how to reward staff for participation in medication management 
programs or how to set expectations for staff participation. The findings from the second study 
suggest that some pharmacies have more experience with relationship building with other 
healthcare providers and therefore implementation assistance may be needed for pharmacies with 
less experience. As an example, pharmacies with less experience working with other healthcare 
providers could be paired with pharmacies with more experience to learn best practices for 
engaging other healthcare providers in medication management services. The findings from the 
third study suggest that some pharmacies may need guidance on the process of implementation 
(e.g., pilot testing, engaging stakeholders prior to implementation) to ensure medication 
management services are implemented effectively and are sustainable.    
Policy Implications  
 The findings from this dissertation suggest that community pharmacies have varying 
levels of experience with implementing medication management services and partnering with 
other healthcare organizations--skills that are required for participating in population health 
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management programs. Given that, it will be important for public payers sponsoring medication 
management programs to test which implementation strategies are associated with effective 
implementation and to encourage grantees (e.g., state Medicaid agencies) to develop 
implementation guidance for community pharmacies and develop mechanisms for sharing best 
practices across high- and low-performing pharmacies.  
The findings from this study also suggest that using staff at the top of their license (e.g., 
pharmacist and pharmacy technicians) facilitates implementation of medication management 
programs. Past studies have shown that, with proper training, pharmacy technicians can assist 
with medication management activities such as gathering patient information and documenting 
medication histories.7-9 Researchers could assess whether state-level differences in regulation 
and recognition of national certification for pharmacy technicians impact the level of pharmacy 
technician involvement in population health management and medication management 
activities.10,11   
Additionally, findings from this study indicate that collaborating with healthcare 
providers and gaining access to patient health information (e.g., EHR access) are challenges for 
community pharmacies participating in medication management programs. Currently, there are a 
number of structural barriers limiting community pharmacist access to EHRs and health 
information exchange (HIE) programs including differences in state laws, user fees for HIEs, and 
lack of reimbursement for community pharmacist use of the EHR.12-14 Since community 
pharmacists are not defined as eligible providers for meaningful use incentives, future 
interventions could test payment models that allow healthcare organizations to share incentives 
with community pharmacists or payment models that support community pharmacist integration 




 The findings from this dissertation suggest several areas for future research. The study 
results from the first study indicated that implementation climate and innovation-values fit work 
in concert to produce effective implementation. Future studies could identify which 
implementation strategies are associated with improved implementation climate and innovation-
values fit. The findings from the second study suggest that some pharmacies are better at 
building inter-organizational relationships in response to changes in the healthcare environment, 
which is consistent with studies of inter-organizational relationships.74,80,88 High-performing 
pharmacies in this study were more effective at creating boundary-spanning roles and leveraging 
external ties to support implementation. Future studies could examine interventions that assist 
community pharmacies with developing inter-organizational relationships to support 
implementation of medication management services (e.g., creation of learning collaborative to 
disseminate effective organizational networking practices). The findings from the third study 
revealed that reorienting community pharmacies from a dispensing to a population health 
management model required a multi-faceted and multi-staged approach to implementation. 
Although high- and low-performing pharmacies utilized many of the same strategies, their 
approach was different, resulting in different implementation outcomes (e.g., acceptability 
among personnel, efficiency, and fidelity91). Future research could identify the core components 
of implementation strategies that are associated with effective implementation of medication 
management interventions—a research need that has been identified in other implementation 
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